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Abstract 
Background:  The association between air pollutants, such as particulate matters (PM) and 
ozone (O3), and the risk of cognitive impairment and hypertension among different age groups 
was deeply investigated. However, limited studies have examined the association between specific 
components of air pollutants, such as polycyclic aromatic hydrocarbons (PAH) with cognitive 
performance (CP) risk and hypertension (HTN) among older adults.  
Objectives of the current study were to examine the association between urinary PAH 
biomarkers and both of CP and HTN in older adults, as well as to determine if the associations 
between PAH and CP scores and HTN differs by individual socioeconomic status and ethnicity.  
Methods: Data from 2011-2014 the National Health and Nutrition Examination Survey 
(NHANES) were used to examine the relationship between urinary PAH metabolites and CP and 
HTN, after adjusting for different covariates. Data analysis included over 3000 NHANES 
participants, aged 60 years and older.  
Results: A significant negative association was found between PAH exposure and CP 
(p<0.001). For each increase in one unit in log-transformed PAH metabolite levels, all cognitive 
tests were lower in almost all models. There was a significant association between urinary 1-
hydroxynaphthalene relative to race and HTN in older adults. Each increase in one unit in log-
transformed urinary 1-hydroxynaphthalene level was associated with greater odds of developing 
HTN for all race groups.  
v  
Conclusion: Higher exposures to PAH were associated with lower CP among males, 
Blacks, Hispanics, individuals with lower education, lower income, and smokers. The higher 
urinary concentration of 1-hydroxynaphthalene in HTN relative to race was among Blacks 
comparing to other ethnic groups. Black individuals with different urinary 1-hydroxynaphthalene 
biomarker concentrations had the highest probability of developing HTN compared to other racial 
groups. 
Public Health Impact: PAH exposures are a significant public health concern that affects 
many countries and cause tremendous negative health outcomes. The effects of PAH not only 
increase the risk of metabolic syndromes and cardiovascular disease, but may also cause mental 
health problems that may affect ethnic groups differently. Thus, recognizing the impact of PAH 
exposure will provide evidence for possible new interventions to combat and mitigate air pollution 
resources.   
  
vi  
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1.1  Overview of Polycyclic Aromatic Hydrocarbons  
Polycyclic aromatic hydrocarbons (PAH) are a group of chemical constituents of particulate 
matters (PM) that are generated by incomplete combustion of organic materials, such as coal, oil, 
gas, exhaust fumes, garbage, and tobacco (Agency for Toxic Substances and Disease Registry 
[ATSDR], 2009). PAH are mixtures of hazardous toxic of genotoxic compounds that are highly 
dispersed in the environment (air, soil and water) (Polanska et al., 2014). PAH are considered as a 
significant public health concern as exposure to PAH, whether acutely or chronically, may increase 
the risk of human diseases, including cardiovascular and lung diseases, as well as cancers (Polanska 
et al., 2014).   
According to the International Agency for Research on Cancer (IARC, 2010), the PAH are 
carcinogenic compounds consisting of carbon and hydrogen that form two to six fused aromatic 
rings structures. There are approximately 16 compounds that are known as carcinogenic-based 
diseases for human, such as benzo[a]pyrene (BaP), (IARC, 2010). Because of their 
physicochemical properties and molecular weights, PAH can persist exist in the environment and 
continue to have biological impact. For instance, PAH that have up to three rings can dissolve in 
water, this chemical structure helps PAH to be more readily available for biological degradation 
(Mackay and Callcott, 1998; Choi et al., 2010). Also, when PAH compounds have more rings (two 
to four rings), PAH volatilize into the atmosphere in gaseous form (Atkinson and Arey, 1994; Srogi, 
2007). However, PAH compounds with more rings (five or more rings) have low solubility in water 
and low volatility into air, therefore, they remain predominantly in solid form and bound to 
2 
particulates in soil or sediment (Choi et al., 2010). More persistent solid PAH are less accessible 
for biological degradation, but more available for human exposure (Johnsen et al., 2005; Haritash 
and Kaushik, 2009). 
1.1.1 Main Sources of PAH 
PAH are released from different sources, including natural sources, such as volcanic 
eruptions or forest fires (Ramesh et al., 2004). However, the major source of PAH is anthropogenic, 
especially from human and industrial activities that include burning of fossil fuels, transportation, 
fumes released from manufacturing industries, and smoking (Figure 1) (Ramesh et al., 2004). 
 
Figure 1 Examples of PAH sources released to the environment (Moorthy, Chu, & Carlin 2015)  
1.1.2 Types, Classifications, and Distribution of PAH 
PAH can be classified into three main groups based on its carcinogenicity to humans. First 
group (Group 1) includes BaP. The second group is subdivided divided into two groups: Group 2A 
and Group 2B. Group 2A is classified as a probable human carcinogens (e.g. cyclopenta[cd]pyrene, 
3 
dibenzo[a,l]pyrene, and dibenz[a,h]anthracene) and group 2B is classified as a possible human 
carcinogens (e.g. benzo [ j] fluoranthene, benzo[k]fluoranthene, benzo[c]phenanthrene, and 
dibenzo[a,h]pyrene) (Figure 2). A third group (Group 3) differs from other groups in that they are 
not classified as carcinogenic to humans (e.g. benzo [a,b,c]fluorene, benzo[a]fluoranthene, 
fluoranthene, and fluorine) (Jameson, chapter 7, 2019). 
 
Figure 2 Examples of selected Polycyclic Aromatic Hydrocarbons (PAH) in the environment (Ramesh et al., 
2016) 
PAH are more concentrated in urban areas than in rural areas as population density, 
industries, and human activities, such as fuel combustion and diesel emissions, are the main 
anthropogenic sources of the PAH emissions. A study using data from the United States 
Environmental Protection Agency (EPA)'s Air Quality System examined the health risk of long-
term exposure to atmospheric PAH in both urbans and rural areas in the United Stated found that 
4 
urban areas had almost twice the PAH concentrations of rural areas (Figure 3) (Liu et al., 2017; 
EPA, 2015). 
 
Figure 3 The spatial distributions of geometric mean of PAH metabolites (ng/m3) between 1990 and 2014 in 
the United States (Copyrighted to: Liu et al., 2017; EPA, 2015)  
1.1.3 Routes of Exposure 
Exposure to PAH can occur in both occupational and non-occupational settings through 
several routs; ingestion, inhalation, and dermal contact. For the general population, inhalation is 
the main route of PAH exposure, including indoor and outdoor polluted air with PAH (e.g. smoking 
cigarettes, cooking, from open fireplaces, exhaust fume emissions or from industries) (American 
Conference of Governmental Industrial Hygienists [ACGIH], 2005). In urban areas, gasoline and 
diesel vehicle exhausts are considered the major source of PAH that released into atmosphere, since 
these areas have higher density of population compared to rural areas where PAH emission would 
be less. 
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1.1.4 Inhalation Route 
As PAH are a toxic mixture of chemicals and hazardous genotoxic compounds, their 
inhalation can increase the risks of different kind of cancerous and non-cancerous diseases. PAH, 
such as BaP, may affect different organs in human body (Moorthy, Chu, & Carlin 2015). For 
instance, in tobacco smoke, there is about 100 ng BaP per cigarette (Grimmer et al.,1988). As a 
result, chronically, smokers may inhale about 0.26 μg of BaP per pack of 20 cigarettes, possibly 
increasing the risk of lung cancer (Piccardo et al., 2010). Additionally, large bodies of literature 
have shown that individuals who smoke cigarettes and cigar may be exposed to much large amounts 
of PAH that can are swallowed and enter the gastrointestinal (Jarup, 2003; Nebert et al., 2013; 
Rozman and Klaassen, 2007).  
1.1.5 Toxicokinetics of PAH 
Toxicokinetic are processes involving the chemical substances at the moment of exposure 
and entry into the body through the elimination of the chemical substance or its metabolites from 
the body (ATSDR, 1995b). These processes are: Absorption, Distribution, Metabolism and 
metabolites, and Excretion.  
1.1.5.1 Absorption of PAH 
PAH adsorbed from inhaling soot particles deposit in the airways or bronchial clearance 
can eliminate those particles. During the transportation process on the ciliated mucosa, PAH can 
also be absorbed from those particles, and consequently, they penetrate into the bronchial 
epithelium cells where other metabolic processes begin (World Health Organization [WHO], 2000; 
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WHO, 2018; ATSDR, 1995b). The absorption level/rate depends on different factors, such as the 
nature of the PAH metabolites. For instance, when BaP is adsorbed on particles, the rate of the 
respiratory uptake might be greater, especially if the particles retained for a long period in the 
respiratory tract (Törnquist, Wiklund, & Toftgård 1985).  
In inhalation studies in rats, animals inhaled radiolabeled BaP adsorbed on diesel engine 
exhaust particles ((Sun et al., 1984)). The inhaled particle-associated radioactivity that occurred 
from the lung clearance underwent through two main phases. In the first phase, the initial rapid 
clearance had a half-time of less than one hour. However, in the second, longer phase, the particles 
had a half-time of 18 days and this represented about 50% of the particle-radioactivity that had 
initially been deposited in the lungs (Sun et al., 1984). Another study demonstrated that exposed 
rats to pure BaP and to [14C] -BaP adsorbed on carbon black particles found inhalation of [14C] -
BaP resulted in hundred-fold higher levels of 14C in lungs at the end of a 12-week. Also, rats 
exposed to [14C] -BaP, the half-time for the decline of [14C] levels was 34 weeks. In contrast, it was 
6 weeks for rats exposed to pure BaP (Wolff et al., 1989). 
1.1.5.2 Distribution of PAH 
After the absorption phase, PAH enter the lymph, circulate in the blood, and are 
metabolized primarily in the liver and kidneys (Busbee et al. 1990). Studies have shown that the 
exposure to BaP can be detected within minutes to hours in internal organs, especially in the liver 
(IARC 1983; Foth, Kahl, & Kahl 1988). In general, PAH are significantly stored in fatty tissues 
(Modica et al., 1983), and high levels of PAH metabolites are found in the gastrointestinal tract as 
the result of hepatobiliary excretion (Schlede, Kuntzman, & Conney 1970; Wiersma & Roth 1983). 
Other studies found some of PAH metabolites, such as pyrene, was highly distributed in the 
perirenal fat, in the liver, kidneys and lungs, however, pyrene concentration levels were less 
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distributed in the heart, testes, spleen and brain (Withey, Law, & Endrenyi 1991; Withey et al., 
1992). Also, BaP has the ability to cross the placental barrier of rats and mice (Neubert & Tapken 
1988; Withey et al., 1993). 
1.1.5.3 Metabolism and Metabolites 
PAH are primarily metabolized by the Phase I cytochrome p450 (CYP) enzymes of the liver 
microsomal mixed fraction is the enzyme system (the CYPs mixed function) in a reaction that 
converts non-polar PAH into polar hydroxy and epoxy derivatives (Hall et al., 1989). The CYPs 
are also widely distributed in other cells and tissues, however, the liver is considered to have the 
highest capacity for PAH metabolism. Compared to the adult tissues, fetal tissues can also 
metabolize PAH, but at a lower rate (Anderson et al., 1989).  
BaP can induce expression of the microsomal monooxygenases and epoxide hydrolases 
CYPs to stimulate its own metabolism (Nebert, Puga, & Vasiliou 1993). Arene oxides and phenols 
are produced as a result of the BaP oxidation. The arene oxides are converted to phenols (3-OH-, 
6-OH-, 7-OH, and 9-OH-BaP), microsomal epoxide hydrolases (hydration) catalyzed phenols to 
trans-dihydrodiols (4,5-, 7,8- or 9,10-dihydrodiol), phenols may also be oxidized further to 
quinones (1,6, 3,6-, or 6,12-quinone). Additionally, secondary epoxides can be formed after further 
oxidation by the CYPs monooxygenase system (IARC 1983; Gräslund and Jernström 1989). 
Furthermore, through biotransformation process, PAH start to exert its mutagenic and carcinogenic 
to chemical reactive intermediates which by then bind to cellular macromolecules (IARC 1983; 
Gräslund and Jernström 1989). 
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1.1.5.4 Excretion 
After metabolism processed, the hepatobiliary excretion of PAH metabolites is eliminated 
and removed from the body through feces (the major route) or urine, regardless of route of entry 
(Foth, Kahl, & Kahl 1988; Wiel et al., 1993). Becher and Bjorseth (1983) reported in their animal 
studies, that the excretion half-life for PAH through both feces and urine was 22 hours and 28 
hours, respectively. 
1.1.6 Systemic Effect of PAH 
As it was mentioned previously, PAH have specific physicochemical properties. These 
compounds are lipophilic, and therefore, after inhalation, they can easily cross cell membranes 
through passive diffusion. The parental PAH molecules (before the transformation or being 
metabolized) could be considered as procarcinogens as they do not directly induce or damage the 
DNA (Alexandrov et al., 2010). The transformation from procarcinogens into effective 
carcinogenic through the CYP metabolism to oxides, phenols, epoxides, and quinones (Figure 4) 
(Moorthy, Chu, & Carlin 2015). 
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Figure 4 Example of multiple mechanisms of PAH metabolites that can cause lung cancer (Copyrighted to: 
Moorthy, Chu, & Carlin 2015) 
The PAH phenol, catechol, and quinone metabolites as well as their diolepoxide precursors 
are radical cations or reactive and redox-active oquinones, and may all react with DNA to produce 
DNA adducts. For instance, quinones may react with both of N-3 of adenine and N-7 of guanine in 
DNA (Liu et al., 2002). The DNA adducts formation can cause mismatch in DNA replication, in 
addition, it can alter the promoter methylation or the promoter binding (Yang et al., 2012), which 
may lead to a mutation in the DNA, abnormal gene expression, and tumorigenesis. Moreover, not 
only DNA adducts can be formed due to the reactive of PAH metabolites, these PAH metabolites 
may also induce protein adducts formation in cells (Berge et al., 2004; Kafferlein et al., 2010), 
which may affect protein structure and its activities. Also, PAH metabolites may induce the reactive 
oxygen species (ROS), which may affect DNA, lipids, or proteins (Kwack and Lee, 2000). 
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1.1.7 PAH Exposure and Dose-Response Relationship 
There are different ways to estimate the internal dose of PAH exposure. This includes 
biomonitoring of PAH concentrations in urine, which is a marker of current exposure as urinary 
PAH metabolites can be eliminated from the body within one day (Best et al., 2016). Kuang et al 
(2013) examined the dose−response relationships between PAH exposure and oxidative stress 
levels of DNA and lipids among 1333 male coke oven workers. The study assessed the correlation 
between total of urinary PAH biomarkers and oxidative lesions in DNA, including both of urinary 
8-hydroxydeoxyguanosine (8-OHdG) (oxidative DNA damage biomarker), and 8-iso-
prostaglandin-F2α (8-iso-PGF2α) (lipid peroxidation biomarker) levels. They found significant 
positive correlations between urinary PAH biomarkers and both of urinary 8-OHdG and 8-iso-
PGF2α levels (Figure 5), the correlation was also positive among smokers and non-smokers after 
adjustment for other confounders (Kuang et al., 2013). 
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Figure 5 The correlation between the total of urinary PAH biomarkers and both of urinary 8-OHdG and 8-
iso-PGF2α levels in the coke oven workers (Copyrighted to: Kuang et al., 2013) 
1.1.8 The Interaction between PAH and other Substances  
Humans usually are not exposed to individual PAH, in general, they are exposed to complex 
mixtures of PAH that can interact with other chemical components. For instance, the exposure to 
chemical mixtures that includes PAH, such as emissions from roofing tar, coal tar, shale oils, and 
coke oven have been reported to have negative association with adverse health effect in humans 
(ATSDR, 1995b). However, the extent of that adverse health effects (whether carcinogenic or non-
carcinogenic) depends on the interaction between the PAH mixture with other chemical 
components. PAH components in cigarette smoke need to interact with other components in the 
smoke in order to start its tumorigenic effect (ATSDR, 1995b; Akin et al. 1976). 
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A large body of literature has shown the interaction between noncarcinogenic PAH and 
carcinogenic PAH in animals. One study concluded that when noncarcinogenic PAH interact with 
BaP, the interaction exhibits a potential of co-carcinogenic, tumor-initiating, and promoting 
activity to the skin of mice. Additionally, the compounds of benzo[e]pyrene, fluoranthene, and 
pyrene increased the BaP-DNA adduct formation (Van, Duuren and Goldschmidt 1976; Van 
Duuren et al., 1973; Rice et al., 1984; Lau and Baird 1992). 
The interactions between PAH components may modify the toxicity level, because PAH 
mixture requires a metabolic activation by monoxygenases to exhibit its carcinogenic effects. 
Therefore, any changes or alteration during the metabolic pathways would affect the observed 
toxicity (Levin et al. 1982). There are different mechanisms by which chemicals may interact with 
PAH to exhibit toxicity; one compound may interact with the same metabolic activating enzymes, 
consequently may reduce the toxicity of PAH-carcinogenic, or a compound may induce the 
metabolizing enzyme levels, consequently may cause more rapid detoxification of PAH-
carcinogenic PAH (Levin et al. 1982; ATSDR, 1995b). 
1.1.9 Industrial Use and Disposal of PAH 
There are different PAH compounds produced commercially in the United States, including 
anthracene, Acenaphthene, fluorene, phenanthrene, and fluoranthene (ATSDR, 1995a). For 
example, anthracene is used in dye production, in the synthetic fibers, and as a diluent for wood 
preservatives, as well as in smoke screens, counter crystals, and in organic semiconductor research 
(ATSDR, 1995a; Hawley 1987). Acenaphthene is used as a dye intermediate, in the manufacture 
of plastics and pharmaceuticals products, and in insecticides and fungicides (Hazardous Substances 
Data Bank (HSDB), 1994; Windholz 1983; ATSDR, 1995a). Fluorene can be used in many 
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chemical processes, such as formation of polyradicals for resins, and in the making of dyestuffs 
(Hawley, 1993; HSDB, 1994; ATSDR, 1995a).  Phenanthrene is used explosives, biological 
research, and in the manufacture of dyestuffs (Hawley 1987; HSDB 1994).  Fluoranthene can be 
added as lining material to protect the interior of steel drinking water pipes and storage tanks 
(National Research Council (NRC) 1983; ATSDR, 1995a).  
PAH are persistent in industrial solid wastes, therefore, the disposal process of these solid 
wastes that contain PAH is a very important in avoiding environmental and human contamination 
(Sisinno et al., 2004). Particle-bound PAH exist in surface waters and needs to be processed and 
removed by sedimentation, flocculation, and filtration processes. However, residual PAH dissolved 
in water require oxidation for partial removal or transformation (EPA 1980). 
1.1.10 PAH and Tobacco Smoke 
Cigarettes contain different chemical compositions as well as numerous toxic and 
carcinogenic PAH components, especially BaP (Vu et al., 2015). It was reported that tobacco 
smoke contains more than five hundred different PAH (Rodgman and Perfetti, 2009). In addition, 
the United States Food and Drug Administration (FDA) identified about 93 harmful and potentially 
harmful compounds in tobacco products and tobacco smoke, sixteen of these compounds are PAH 
(FDA, 2012). 
Since the main route of PAH exposure is inhalation, the dose of PAH exposure can be 
measured by the level of PAH concentrations in the lung tissues. Goldman et al. (2012) measured 
eleven PAH compounds in 70 samples of lung tissue (cancer-free), donors were 37 smokers and 
33 nonsmokers, as estimated by serum cotinine concentration, the study found that the higher 
concentration of total PAH was among smokers. There was a dose-response relationship for greater 
14 
smoking, and they also stated that tobacco smoke increased concentrations 5 types of PAH in lung 
tissues including BaP. They also found higher PAH concentrations in lung tissues in males relative 
to females. In addition, black males had a higher concentration of PAH in lung tissues compared 
to other ethnic groups (Goldman et al., (2012). 
1.1.11 PAH Exposure and Public Health Perspective  
PAH exposure is considered to be a growing public health issue, many studies indicate that 
certain PAH can be carcinogenic to humans and animals. PAH exposure in humans comes mostly 
from occupations that involve PAH mixtures, such as roofing, oil refining, or coal extractions and 
other work-related PAH exposures (ATSDR, 1995b). As it was mentioned previously, adverse 
health effects of PAH exposures in animal experiments have shown that several PAH components, 
including BaP, benzo[b]fluoranthene, chrysene, and other chemical components can cause tumors 
and different carcinogenic effects, regardless of whether the PAH exposure was by inhalation, 
ingestion or by long-period of skin contact exposure. Studies also have shown the cancerous effect 
in humans after long-period of PAH exposure, especially by the inhalation routes (ATSDR, 1995b).   
The biggest public health concern is with the mortalities related to the PAH exposure. An 
old study conducted in animals found that the exposure to BaP for total period of 109 weeks was 
related to reduced-survival of hamsters after 60 weeks of BaP inhalation. The study concluded that 
the toxic and carcinogenic effects of BaP might be the cause of the reduced-survival of hamsters 
(Thyssen et al., 1981). A recent study found that PAH exposure was linked to increasing risk of 
all-cause mortality and the study concluded that PAH metabolites were associated with increased 
risks of cancers, cancer mortality, and possibly cardiovascular disease mortality among adults aged 
20 years and older (Chen et al., 2021).  
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The exposure to PAH can be vary within different geographic regions, studies reported that 
residents of the environmental justice neighborhood can be disproportionally exposed to toxic air 
pollutants including PAH from both industry and transportation infrastructure, which would 
increase the negative health consequences among minorities and vulnerable population (Sansom et 
al., 2018). Communities efforts and research projects attempted to investigate these discriminatory 
environmental exposures, however, the type of these observational studies did not provide an 
inadequate evidence by both researchers and affected communities (Bowen, 2002; Sansom et al., 
2018). 
Multiple large studies showed an evidence of the link between air pollution including PAH 
exposure and socioeconomic status. A study reported that Non-Hispanic blacks and Hispanics were 
living in counties that had highest air pollutants concentrations, such as fine particulate matter 
diameter less than 2.5 micrometers (PM2.5), O3, and PAH (Miranda et al., 2011). Another research 
study reported that non-Hispanic blacks, unemployed individuals with low income and low 
education level were living in areas with higher exposures to different air pollutants (Bell and 
Ebisu, 2012). The variation in the health of disadvantaged populations can be explained by different 
reasons, for instance, residential segregation is an important factor that plays a big role of determine 
why communities differ in air pollutants exposures (Massey and Denton 1993). The racial 
differences may face greater exposure to different air pollutants, especially the carcinogenic PAH 
group, such as BaP, that could be because of different factors, for instance, racism, class bias, land 
costs, and housing market dynamics (American Lung Association, 2020). 
From a public health perspective, the adverse health effects as a result of PAH exposure, 
depend on how long the individual has been exposed to PAH (short-term or long-term exposure), 
the amounts or quantities of PAH toxicants entered the body, and how the body reacted and 
responded to PAH (Kim et al., 2013). It still not clear whether the exposure to PAH itself for short-
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term may cause adverse health effects, however, it was reported that other chemical compounds 
that exist in PAH may be the cause adverse health effects for short-term, such as nausea, vomiting, 
diarrhea, eye irritation, and cognitive disorders (Sun et al., 2021). On the other hand, long-term 
exposure to PAH may cause cataracts, kidney and liver damage, and jaundice, also, inhaling large 
amounts of naphthalene can cause the breakdown of red blood cells (Sun et al., 2021). 
The exposure to PAH may have different negative health consequences. Different 
epidemiological research studies have found that PAH exposure may cause neurobehavioral 
disorders, such as cognitive impairment (Wormley, Ramesh, and Hood, 2004). Also, PAH from 
the environment or tobacco smoking constitute another modifiable exposure that can increase the 
risk of hypertension, which also increases the risk of cardiovascular diseases (Abboud and 
Karam, 2021; Sancini et al., 2014; Zhang et al., 2021; Shiue, 2015). The effect of PAH exposure 
on cognition and increasing the risk of hypertension may also differ with age, gender, and race. 
1.2 Overview of Cognitive Impairment  
1.3 Cognitive Impairment Among Older Adults  
Cognitive impairment or cognitive decline is defined as confusion or memory loss that 
generally affects older populations (Centers for Disease Control and Prevention [CDC], 2009). 
Individuals suffering cognitive impairment may experience difficulty or trouble memorizing, and 
may have difficulty in learning new things, concentrating, or making decisions. All of which may 
affect their daily life activities (CDC, 2009). Approximately 20% of the United States population 
of adults aged 65 years and over have some form of cognitive impairment, such as Alzheimer 
disease and dementia (Karel, Gatz, & Smyer, 2012; Best et al., 2016).  
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The geographic distribution of the cognitive impairment among different age groups in the 
United States varies. For instance, the percentage of adults with cognitive impairment aged 50 years 
and older ranged from approximately 9% in Iowa to 15% in Michigan (Figure 6) (CDC, 2009). 
 
 
Figure 6. The percentage of adults with cognitive impairment within different states and age groups (CDC, 
2009) 
1.3.1 Cognitive Impairment Classifications and Measurements 
Cognitive impairment can be classified as mild or severe forms with about 10 to 20 percent 
having mild cognitive impairment (MCI) among age group of 65 years or older (Best et al., 2016). 
People with MCI can perform their activities of daily lives normally, however, they may notice 
some changes in their cognitive functions or behaviors. On the other hand, people with severe 
cognitive impairment may experience more difficulties, such as losing the ability to understand, 
talk, or write, which impairs their normal lives and the ability to live independently (CDC, 2009). 
Clinically, cognitive function can be measured by different procedures. The Consortium to 
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neuropsychological tests performed to measure cognitive impairments and assess patients with 
clinical diagnosis of Alzheimer's disease (Fillenbaum et al., 2008).  
1.3.2 Cognitive Tests Assessment 
CERAD consists of different tests that can be performed to examine the cognitive function 
among adults. The cognitive tests battery includes: Digit Symbol Substitution Test (DSST), Word 
list learning (WL), Delayed Word Recall test (DWR), and Animal Fluency (AF) (Brody et al., 
2019). 
DSST is a subtest performed to assess psychometric cognitive and executive function, 
including attention, motor and processing speed, and visuoperceptual functions (writing, drawing, 
or scanning) (Jaeger, 2018).  The DSST is performed by giving the individual a single sheet of 
paper to match symbols to numbers according to a key located on the top of the page, the individual 
needs to copy the symbol and correctly match it with its number within 90 to 120 seconds. For each 
correctly matched symbol–number pair, a one point was giving for a total score of 105 (CDC, 
2014a).  
The DSST is a common test that has been used in most all neuropsychology assessment 
tests due to its high sensitivity for detecting MCI (Rosano et al., 2016). DSST can also be used to 
detect the short-term effect of alcohol consumption or drugs after administration on the cognitive 
changes (Wang et al., 2013; Evans and Levin, 2004). Proust-Lima and colleagues (2007) conducted 
a cohort study on elderly French adults and found that DSST is highly sensitive to cognitive 
changes. DSST could detect a one-point change in DSST score in adults who scored 25 or above 
when performing a cognitive examination (Proust-Lima et al., 2007). 
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WL and DWR tests can assess cognitive changes by evaluating the verbal learning (to assess 
new verbal learning, the immediate and delayed memory) among older adults, which may help in 
early diagnosis of Alzheimer's disease (CDC, 2014a). WL test consists of three consecutive 
learning trials, each trial list contains 10 un-related words (same words for each of three trials but 
in different order). Words were read aloud, then, the participants were asked to recall as many 
words as possible (immediate recall). For the three trials, 1 point was given for each word recalled 
for a total score of 30 (CDC, 2014a). DWR consists of ten separate words, the individual reads 
aloud those words from a computer screen, then is asked to recall them after performing another 
unrelated task or after a delay. The test is scored by giving 1 point for each word recalled for a total 
score of 10 (Lyness et al., 2014a). 
AF test is performed to examine verbal/semantic fluency, which is considered as a 
component of executive function. The test is performed by asking the participants to name as many 
animals as possible in one minute. AF test scored by giving 1 point for each named animal for a 
total score of 40 (CDC, 2014a). 
1.3.3 Factors that Affect Cognitive Performance 
Different studies have examined the factors that may contribute to progressive cognitive 
decline among older adults. For instance, age and genetic susceptibility are strong risk factors that 
may increase the risk of cognitive impairment among different age groups (Hendrie et al., 2006, 
CDC, 2009; Best et al., 2016). It is well documented that genetic factors are the major risk factors 
for cognitive function decline that leads to developing Alzheimer’s disease (Todd et al., 2017; 
Rawle et al., 2018; Emrani et al., 2020). Apolipoprotein E (APOE) is the primary genetic risk factor 
that plays a big role in the onset of dementia and Alzheimer’s disease. APOE is involved in 
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cholesterol and other lipid metabolism and transport between cellular structures, as well as playing 
a major role in clearing β-amyloid from the brain (Todd et al., 2017).  
APOE consists of ε2, ε3 and ε4 alleles. The ε4 has the highest rate of lipoprotein clearance, 
therefore, it can affect plasma cholesterol level as well as disrupt brain re-innervation processes 
that rely on lipids (Rawle et al., 2018). Possession of the ε4 allele (especially homozygosis carriers) 
is considered as the primary genetic risk factor for developing cognitive function impairment, 
Alzheimer’s disease, and dementia (Emrani et al., 2020). It was reported that APOE ε4 carriers are 
experiencing more memory declines rapidly than in APOE ε4 noncarriers (Caselli et al., 2004).  
Metabolic syndrome, including cardiovascular diseases (heart diseases, hypertension, and 
stroke), lung disease, diabetes, and tobacco smoke, are also considered possible risk factors that 
play a strong role in developing cognitive decline among the elderly (Zhang et al., 2015; Hendrie 
et al., 2006, CDC, 2009; Best et al., 2016). Additionally, different studies have shown that 
environmental factors, such as pesticides and ambient air pollution could be potential risk factors 
for cognitive decline overtime with age (Bouchard et al., 2014; Kim et al., 2015; Loop et al., 2013; 
Weuve et al., 2012; Gatto et al., 2012; Chen and Schwartz, 2009; Best et al., 2016). 
1.3.4 Cognitive Decline and Public Health 
Cognitive impairment is considered a growing public health issue, cognitive decline can 
interfere with people behaviors, activities, and in their daily lives. Regardless of whether it is 
subjective cognitive decline (SCD) (a self-reported experience of confusion or memory loss) 
(Jessen et al., 2014) or actual cognitive decline, both types are considered as subtle markers of early 
symptoms of Alzheimer’s disease, which is also an emerging public health concern (CDC, 2017). 
Cognitive impairment may affect a person’s ability to effectively manage their personal treatment 
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plans and taking their daily medications, which can result in poor health outcomes of comorbid 
chronic diseases, such as diabetes and cardiovascular diseases (CDC, 2017).  
According to Silvaggi et al. (2020), about 10–20% of people aged under 65 may have early 
onset dementias or MCI, which may not significantly impact their work performance and allow 
them to remain active and in the workforce (Silvaggi et al., 2020). However, early onset dementias 
or MCI may affect and reduced their work ability and their work-related activities (WHO, 2012). 
Due to a normal decline of cognitive ability and motor functioning, older workers have lower ability 
to learn, more difficulty in training, and are less flexibility in performing their work tasks during 
routine work hours (Mutlu et al., 2018).  
A recent study found that individuals with MCI or early onset dementias tend to leave their 
work, considered as a job loss (Sakata and Okumura, 2017). The study involved 220 participants 
aged 40–59 with early onset dementias against 1100 age and gender-matched controls with non-
MCI or any type of dementias. The study stated that after the period of two and half months and 
after the participants received their diagnosis of early onset dementias, there was an increase in 
leaving one’s job. After six months, approximately 9.1% of participants with early onset dementias 
and 3% of controls left their job as well (Sakata and Okumura, 2017). 
1.3.5 Racial Demographic of Cognitive Impairment in the United States 
Racial and ethnic disparities in cognitive impairment may differ in prevalence for each 
racial group. For instance, to identify disparities in prevalence of SCD among different racial 
groups in the United States population, it was reported that during 2015–2018 of about 180,000 
participants aged 45 years or older who participated in a SCD screening, 19,276 had SCD with 
some other chronic conditions. The prevalence of SCD was; 10.7% in Whites, 12.3% in Blacks, 
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and 9.9% in Hispanics. Additionally, Blacks and Hispanics with SCD were had less education 
level, lower income, less access to health care, and more functional limitations (Gupta, 2021). 
Another study examined the differences in cognitive function between different race and 
ethnic groups in the United States population (Díaz-Venegas et al., 2016). This study used in-
person or by telephone interview with a modified version of the telephone interview for assessing 
cognitive status among 19,000 participants. They found that Hispanics and Blacks had lower 
cognition scores than Whites for all age groups (51–59, 60–69, 70–79, 80 and over) (Figure 7) 
(Díaz-Venegas et al., 2016). 
 
Figure 7 Predicted cognitive scores of participants aged 52 years and older by race/ethnicity (Díaz-Venegas et 
al., 2016) 
1.4 Overview of Hypertension  
Several epidemiological studies provide evidence that elevated blood pressure or 
hypertension (HTN) (defined as systolic and/or diastolic BP ≥140/90mmHg) is a major risk factor 
for cardiovascular disease (CVD), the leading cause of death in worldwide (WHO, 2004; Bangia 
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et al., 2021; Abboud and Karam, 2021; Aryal, Harmon, and Dugas, 2021). HTN is considered a 
major cause of disability and a leading to risk factor for death worldwide (DeGuire et al., 2019). 
It was estimated that the prevalence of hypertension is approximately 30 - 40% of the global 
population (Pereira et al., 2009), and it expected to increase with advanced aging of the 
population (Myers, 2007). 
There are two types of high blood pressure; primary (essential) hypertension that occurs 
with no identifiable or specific cause, developing over many years and secondary hypertension 
caused by an underlying condition, such as kidney disease, thyroid problems, adrenal gland 
tumors, obstructive sleep apnea, and some drugs, including cocaine and amphetamines (Mayo 
Clinic, 2021). There are different risk factors that can increase the risk of the HTN including age, 
race (more common among African heritage), family history, obesity, tobacco smoke, alcohol 
consumption, diet (e.g. consuming too much sodium salt and less amounts of potassium), lack of 
physical activities, stress, and chronic disease (Mayo Clinic, 2021). 
There are different complications for the HTN that can lead to serious health 
consequences and life-threatening conditions, such as heart attack or stroke, aneurysm, heart 
failure, weakened and narrowed of blood vessels in the kidneys, metabolic syndrome (including 
increased of waist size, high triglycerides, decreased high-density lipoprotein (HDL)), memory 
decline, and Dementia (vascular dementia) (Mayo Clinic, 2021). 
Other environmental factors such may also increase the risk of developing HTN. Ambient 
air pollution is a well know environmental factor associated with developing HTN (Giorgini et 
al., 2016). For instance, fine particulate matter diameter less than 2.5 micrometers (PM2.5) is an 
air pollutant that can increase HTN risk whether in short (3 and 4 weeks) or long-term (1 to 3 
years) exposures (Wellenius et al., 2012; Dong et al., 2013). 
Additionally, various epidemiological studies examined the association between PAH and 
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HTN, one study found an association between hydroxypyrene (1-OHPr) (one component of PAH) 
and HTN among outdoor workers (Sancini et al., 2014). Another study assessed the association 
between different PAH types with HTN, and reported that urinary 4-hydroxyphenanthrene was 
associated with hypertension (Shiue, 2015). A recent study also found an association between 
different PAH and HTN (Bangia et al., 2021).  
1.4.1 Racial Demographic of Hypertension Incidence in the United States 
According to the CDC, during the period of 2015-2016 that the percentage of HTN cases 
occur more in men (51.0%) than woman (39.7%) (CDC, 2020). Among men, the percentage of 
HTN cases occur more in Black (57.2%) compared to White (50.2%), and Hispanic (50.1%) 
adults. Among women, the percentage of HTN cases occur more in Black (56.7%) compared to 
White (36.7%), and Hispanic (36.8%) adults (Figure 8) (CDC, 2020). 
 
 
Figure 8 The prevalence of hypertension among adults aged 18 and over, by sex and race in the United States, 
between 2017–2018 (CDC, 2020) 
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1.5 Hypothesis and Aims 
As indicated, PAH are a public health concern and the exposure to PAH, whether acutely 
or chronically, may increase the risk of human diseases among different age, race and ethnic groups 
worldwide. Multiple reports have shown an association between PAH and cognitive impairment 
among young age groups and there are some reports assessing the association between PAH 
exposure and CVD, including the association with developing the risk of hypertension. These 
studies concluded that the exposure to PAH may affect cognitive performance, and also may affect 
the developing the risk of hypertension among older adults.  
This dissertation research investigated two aims: 1) the hypothesis that exposure to PAH 
may reduce the cognitive performance in the older population and that effect would differ in race 
groups; and 2) the hypothesis that the effect of PAH exposure on hypertension may change with 
race among older adults. 
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2.0 The Association between Polycyclic Aromatic Hydrocarbons Exposure and Cognitive 
Performance in the United States Older Adults 
In review by Plos One, June 2021 
2.1 Introduction 
The World Health Organization (2020) reported that the fast-growing elderly population, 
especially in developing countries, will increase dementia to a global epidemic in the near future. 
As life expectancy has doubled recently (Environmental Pollution Centers, 2017), different studies 
considered aging as a result of lifelong damage to cells and tissues overtime (Kirkwood, 2008), 
which may harmfully affect the cognitive performance (CP) among this age group (Salthouse, 
2009). According to the Alzheimer`s Association (2018), dementia and cognitive decline are major 
remarkable mental disorders in older people. Statistically, the prevalence of cognitive decline 
among adults aged 65 years and over is about 30-40% and may increase with increasing age.  
Different epidemiological studies and laboratories experiments have found that PAH 
exposure can cause neurobehavioral deficits (Wormley, Ramesh, and Hood, 2004). Globally, 
children born in early 1980s in the Czech Republic were experienced learning disorders, these 
children were presumed to be exposed to PAH in utero due to the increased levels of PAH that in 
mining and combustion of coal (Otto, Skalik, and Bahboli, 1997). The long-term exposure to B[a]P 
had developed neurotic syndromes with vegetative dysregulation and a loss of short-term memory 
among workers in Coke production factories in Poland (Majchrzak, Sroczyński, and Chełmecka, 
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1990). From the period-time of 1960s until the 1970s, some neurological symptoms were noted 
and reported from a community in Texas during the chronic exposure to different PAH biomarkers, 
such as B[a]P, naphthalene, fluorine, and pyrene products that were dumped at nearby national 
priorities list (NPL) hazardous waste sites. Same in the state of Louisiana, residents who were living 
close proximity to a combustion superfund site had also neurophysiological problems (Dayal et al., 
1995). 
2.1.1 PAH and Neurodegenerative Diseases 
The plausibility of these associations has been demonstrated in animal studies that found 
that exposure to B[a]P may cause acute neurobehavioral toxicity through oxidative stress (Saunders 
et al., 2006) poor performance in running after short-term exposure to fluorine and naphthalene 
(other PAH components) (Peiffer et al., 2013; Kilanowicz et al., 2012). 
A recent study was conducted on rats mentioned that B[a]P exposure at early gestation may 
lead to learning and memory deficit in offspring rats and may affect the neuronal survival in their 
later-life, the study also demonstrated that B[a]P exposure caused a notable reduction of 
hippocampal neurons and glial cells at early gestation when compared with the control group (Das, 
Patel, and Patri, 2019). These results reveal how the PAH exposure affects learning and memory 
over time-period, these results could be applied as well on human, however, further research 
projects and experiments are needed to determent the molecular mechanism and the cellular 
interaction with PAH components to understand the role of PAH and its effect on learning and 
memory behavior in adults. 
The neurotoxic effects of PAH exposure have been reported. Das, Patel & Patri (2011) 
found that early exposure to Benzo[a]Pyrene (B[a]P) (a high molecular weight PAH constituent of 
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tobacco smoke) may lead to pathogenic reduction in dopamine neurotransmitter level leading to 
neurodegenerative diseases and neurobehavioral perturbation in adolescence. Maternal/fetal PAH 
exposures have been linked to developmental have been associated with cognitive deficits in 
childhood that can affect behavior, as well academic performance (Perera et al., 2011). Cho et al. 
(2020) demonstrated that the exposure to PAH was associated with cortical thinning, and decline 
in verbal learning and memory function in healthy adults. 
2.1.2 PAH Exposure (Prenatal Development and Genotoxic Effect) 
Several studies suggest that PAH exposure during the prenatal and early postnatal stages 
might affect the developing of fetus and infant (Polanska et al., 2014). It has been reported in 
different studies that PAH concentrations were found in placental tissues and umbilical cord blood 
(Polanska et al., 2014; Perera et al., 2005), which may suggest that the transfer of PAH biomarkers 
and other chemicals can across the placenta and fetal blood brain barrier, consequently, would 
affect and increase the risk of intrauterine fetal development, growth restrictions, small gestational 
age, and preterm delivery (Dejmek et al., 2013; Choi et al., 2008). 
Importantly, the prenatal exposure to PAH have an impact on fetus parameters at birth, such 
as birth weight, length, as well as on head and chest circumference (Polanska et al., 2014; Polańska 
et al., 2010). These parameters were correlated with severe intrauterine growth restriction, poor 
neurodevelopmental disorders, and subsequent morbidity and mortality (Bassan et al., 2005; 
Leitner at al., 2007).  
Furthermore, it has been reported that prenatal exposure to PAH may affect the infants’ 
neurodevelopment, for instance, it may decrease cognitive and motor functions, reduce child IQ, 
and increase risk of behavioral problems (Perera et al., 2006; Wang et al., 2010). According to Choi 
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et al. (2008) a one unit increase in prenatal PAH exposure was associated with a 0.04% increase in 
cephalization index. A cohort study that was conducted in New York City illustrated that prenatal 
exposure to PAH was associated with developmental delay at age of 3 years and reduced IQ at age 
of 5 years (Perera et al., 2009).  
Different studies have provided an evidence that prenatal exposure to PAH has been 
associated with behavior, brain gene expression, impaired neurocognition, and increased anxiety 
(Chu et al., 2013; Yan et al., 2014). Miller et al. (2016) found that the prenatal exposure to PAH 
was associated with altered behavior, gene expression reductions, and elevation in brain-derived 
neurotrophic factor (Bdnf) DNA methylation within the cortex in adulthood mice. 
2.2 Hypothesis and Aims 
The link between air pollutants, such as PM and ozone (O3), and the risk of cognitive 
impairment among younger individuals has been shown in recent studies (Peters et al., 2019). 
However, limited studies have examined the association between specific components of air 
pollutants, such as PAH, and cognitive decline risk among older adults. 
We hypothesize that the exposure to PAH may reduce the CP in older population. Most 
studies have focused on addressing the relationship between PAH and cognitive assessment among 
newborns and young age groups. However, there are knowledge gaps regarding understanding the 
impacts of PAH on CP among older adults. Different studies mentioned the risk of environmental 
factors including air pollution for developing dementia in the elderly (Killin et al., 2016). However, 
one study conducted over a time-period of two years (2001-2002) and the DSST did find a negative 
association between PAH and cognitive decline among older adults (Best et al 2016).  
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To expand on the previous findings, we examined a battery of four cognitive tests (DSST, 
DWR, WL, and AF) over four years (2011-2014) in a larger cohort of older adults along with an 
expanded battery of urinary PAH biomarkers (1- and 2-hydroxynaphthalene (1-OHN and 2-OHN), 
2- and 3-hydroxyfluorene (2-OHFl, 3-OHFl), 1-, 2-, and 3-hydroxyphenanthrene (1-OHPhe, 2-
OHPhe, 3-OHPhe), and 1-hydroxypyrene (1-OHPyr)) to determine associations between CP and 
PAH exposure. This allowed stratification of exposures and clinical outcomes on the basis of sex, 
race, ethnicity, and socio-economic status. 
2.3 Materials and Methods 
2.3.1 Ethics Statement 
The data were exempt from human subjects review as this study used public dataset 
(NHANES 2011-2014) that were anonymized and de-identified before it was analyzed. 
2.3.2 Study Population and Data Collection  
Data were obtained from National Health and Nutrition Examination Survey (NHANES) 
for the years 2011-2014. NHANES is a series of cross-sectional surveys conducted by the National 
Center for Health Statistics (NCHS), which is part of the Centers for Disease Control and 
Prevention (CDC). NHANES uses complex and multistage design sampling aims to select random 
samples that contain a specific number of noninstitutionalized civilians across the United States. 
For each cycle year, the random selected sample data consist of demographic, social, behavioral, 
dietary, clinical, and laboratory analysis that performed by interviews and physical examinations.  
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The data survey analysis for this study consists of household interviews and physical 
examinations performed in a mobile examination center (MEC). Eligible individuals included all 
adults aged 60 years and over with urinary PAH metabolite measured and with four assessed 
cognitive tests DSST, DWR, WL, and AF were obtained from NHANES 2011-2014 surveys. 
Cognitive function assessment was obtained from NHANES surveys either during 
household interviews or in the MEC centers for the period of 2011 to 2012 and for 2013 to 2014. 
CP was assessed, but for limited number of cognitive subdomains, such as working memory, 
processing speed, and executive functioning evaluation. The CERAD battery module for this study 
will include DSST, DWR, WL, and AF, and will treated as continuous variables. 
2.3.2.1 Urinary Biomarkers of PAH  
The urine samples were collected from participants at MEC, the samples were stored under 
low temperature (–20°C), and sent to National Center for Environmental Health for farther analysis 
(CDC, 2014b; CDC, 2016). The analysis procedure included enzymatic hydrolysis of 
glucuronidated/sulfated OH-PAH metabolites in urine to remove PAH conjugates, extraction 
including mono-hydroxylated PAH metabolites. The urinary metabolites were analyzed using 
isotope dilution capillary gas chromatography with high-resolution mass spectrometry (GC-
MS/MS) (CDC, 2014a; CDC, 2016). Some of PAH metabolites results were below the lower limit 
of detection (LLOD), for that reason, a value was imputed as a lower limit of detection divided by 
square root of 2 (CDC, 2014a; CDC, 2016). 
For this study, urinary PAH biomarkers were categorized into three groups based on its 
molecular weights: 
1.  Total of all urinary PAH metabolites (1-OHN, 2-OHN, 3-OHFl, 2-OHFl, 3-OHPhe, 1-
OHPhe, 2-OHPhe, and 1-OHPyr). 
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2. Total of smaller molecular of PAH (NFP) that include 1-OHN, 2-OHN, 2-OHFl, 3-OHFl, 
OHPhe, and 2-OHPhe. 
3. 1-OHPyr. 
Measure of urinary creatinine was added as a potential confounder in linear regression 
models to account for PAH biomarker variation due to differences in urine dilution. Each urinary 
PAH biomarker group was used as predictor for each cognitive test in separate linear regression 
model. To satisfying normality assumptions, we took the natural logarithmic transformation of all 
PAH metabolite measures for all statistical analyses.  
2.3.2.2 Socio-Demographic Variables, Risk Factors, and Confounders  
The study cohort consisted of 3,181 adult survey participants who had one or more 
cognitive test scores (Figure 9). Data were used to examine the association between the urinary 
PAH biomarkers and cognitive tests after adjusting for risk factors, such as age, socio-economic 
status, medical conditions, cardiovascular diseases, diabetes, tobacco smoking, alcohol 
consumption, kidneys problems, lack of physical activity, and self-reported assessment physical 
function limitations. The risk factors, were categorized into different groups similarly to earlier 
studies (Best et al., 2016) 
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Age at the time of screening is categorized into three groups: 60–69, 70–79, and 80 and 
over. Race and ethnicity groups are classified as Whites, Blacks, Asians, and Hispanic. Sex was 
categorized as male or female. Annual family income was collected as a range value in US dollars 
and categorized as low income (<25,000), middle income (25,000-54,999), and high income 
(>=55,000). Education level was classified into four groups: having less than high school 
education, having completed high school or a GED (high school equivalency diploma), having 
some college, or being a college graduate or higher. Smoking - cigarette use was classified as 
smoker (individuals who smoked at least 100 cigarettes in entire their lives or non-smoker (smoking 
less than 100 cigarettes in life) (yes/no). Alcohol consumption was categorized into Alcohol drinker 
(drinking more than 12 alcoholic drinks a year) or non-drinker (drinking less than 12 alcoholic 
drinks a year) (yes/no). 
 Medical condition variables were constructed on self-reported answers (yes/no) for 
different health aspects, such as heart diseases (congestive heart failure, coronary heart disease, 
angina/angina pectoris, heart attack), stroke, emphysema, memory and thinking. Diabetes was 
categorized into diabetic as self-reported answers (yes/no) (individuals who have been told by 
doctors that they are diabatic) or not diabetic. Kidney problems were categorized as self-reported 
answers (yes/no) for individuals who had kidney problems (who have been told that they have 
weak or failing kidneys), or individuals who were not aware of kidney problems. Physical activity 
variable included participants who reported (yes/no) that they practice and engage in daily 
activities, such as vigorous work activity, walking or using bicycle, or practicing some vigorous 
recreational activities. Physical functioning limitation variable measured self-reported functional 
limitation conditions that was caused by long-term physical, mental, and emotional problems, for 
instance, limitations that keep individual from working, limited work amount that individual can 
does, or if individual experiences any confusion or memory problems.  
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Body mass index (BMI) is defined as weight in kilograms divided by height in meters 
squared, this variable was categorized into three groups normal (<25), obese (25-29.9), and over 
weight (=>30). Blood pressure and cholesterol variable was categorized into individuals who have 
hypertension (participants take prescribed medicine for hypertension) or non-hypertension, as self-
reported answers (yes/no), for cholesterolemia, it was categorized into individuals who have high 
cholesterol in blood (taking prescribed medicine for cholesterol) or individuals who do not take 
medicine for cholesterol as self-reported answers (yes/no). 
2.4 Statistical Analysis 
2.4.1 Descriptive Statistics  
Descriptive statistics used to characterize the study participants included counts, means, 
and standard error (SE) for continuous variables for both cognitive scores and urinary PAH 
biomarkers. Counts, percentages (weighted), SE for categorical variables. Missing data (N) was 
not included, since NHANES collected the sample data randomly. 
Univariate linear regression analyses were used to measure the association of CP scores and 
urinary PAH biomarkers for each individual risk factor in separate models (Models 1-4) (S1 
Appendix). This tested for statistically significant associations between each covariate and 
cognitive tests and only significant co-factors were included in the multivariate model. The linear 
regression model is: 
 y= βo + β1log(X1), 
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where y is DSST, DWR, WL, or AF score for each individual, βo is the intercept of the regression 
line, β1 is the slope of the regression line, X1 is the logarithm of the PAH biomarker concentration. 
Furthermore, categorical variables were dummy-coded to create reference groups. Dummy 
variables allowed for multiple comparisons in a single multivariate model while controlling 
experiment wise error. 
Multivariate linear regression analysis was used to measure the independent association of 
CP scores with urinary PAH biomarker groups for the significant covariates identified in the 
univariate models. A single multivariate model was constructed for each cognitive test. These 
models (models 5-8) (S1 Appendix) utilized the dummy coded variables used in the univariate 
models. The multivariate linear regression models are:  
y = βo + β1log(X1) + β2log(X2) + β3log(X3) . . . + e, 
where y is the DSST, DWR, WL, or AF score for each individual, βo is the intercept of the 
regression line, β1 is coefficient of the regression model that represents the change in the mean of 
the DSST, DWR, WL, or AF score for each unit change in the log of a specific PAH biomarker, 
X1 is the logarithm of a specific PAH biomarker, X2 is another covariate to adjust for in the model, 
e is the error term. 
All data were analyzed using SAS Version 9.4  
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2.5 Results 
2.5.1 Descriptive Statistics 
Descriptive statistics were generated for demographic variables (Table 1) (S1 Appendix). 
The majority of participants were between 60 and 69 years old (~55%), also, the percentage of 
female participants was higher than males 55% to 45%. Additionally, the percentage of white 
participants was the highest 78%. Table 2 (S1 Appendix) represents mean and SE for DSST, DWR, 
WL, and AF test scores. Overall, the mean score for DSST, DWR, WL, and AF were 52, 6, 19, and 
18 respectively. Table 3 (S1 Appendix) shows descriptive statistics for mean and SE for urinary 
biomarkers of PAH. Overall, the mean urinary biomarkers concentration for each of PAH-total and 
PAH smaller molecular metabolites was approximately the same (55000 ng/L), and for 1-OHPyr 
metabolites was 137 ng/L. 
Table 4 (S1 Appendix) shows the descriptive statistics for categorical variables by urinary 
PAH metabolite groups, and for DSST, DWR, WL, and AF scores. Males had higher urinary PAH 
metabolite concentrations than females, as well as lower scores in all cognitive tests. Participants 
with low income (<$25000) had relatively the highest urinary PAH metabolites and lowest test 
scores comparing to middle and high income. Blacks had the highest urinary PAH biomarkers 
concentrations (Figure 10). Also, Hispanics and Blacks had the lowest DSST scores (Figure 11). 
Smokers had the highest urinary PAH metabolite concentrations and lowest test scores comparing 
to non-smokers. Overall, whites had the highest smoking rates (~48%) compared to other ethnic 
groups (Figure 12). 
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Figure 12. Smoking rates by race and ethnicity (p<0.001) 
 
2.5.2 Univariate Linear Regression 
The univariate linear regression analysis evaluated the relationship between DSST score, 
and urinary PAH metabolites groups and each covariate of interest using separate models (Table 
5) (S1 Appendix). A negative significant association was found between all urinary PAH 
metabolites and DSST score (p<0.001). In addition, all other variables, including age (categorical), 
education level, annual family income, smoking status, and physical activity were also significantly 
associated with DSST score. Individuals aged 80 years and over were associated with poorer 
performance on the DSST, conversely, younger age participants were associated with better 
performance on the DSST. Blacks participants had poorer performance on the DSST comparing to 
another ethnic group performance on the DSST.  
Table 6 (S1 Appendix) represents univariate linear regression analysis that examined the 
























significantly associated with the DWR score (P<0.001), including age, gender, ethnicity, and 
annual family income. Individuals aged 80 years and older, Blacks, and participants who had a 
lower educational level were associated with poorer performance on the DWR. 
Table 7 (S1 Appendix) shows univariate linear regression analysis that assess the WL score 
and each covariate of interest using separate models. Age, gender, ethnicity, education, annual 
income, smoking, alcohol consumption, and other variables were significantly associated with the 
WL score (P<0.001). Individuals aged 80 years and older, Hispanic group, and participants who 
have less educational level were associated with poorer performance on the WL cognitive test. 
In Table 8 (S1 Appendix), a significant negative association was found between urinary 
PAH (only for each Log transformed of PAH total and PAH NFP metabolites) and AF score 
(p=0.03). In addition, all other variables, including age, race and ethnicity, education level, annual 
income, alcohol consumption, and other covariates were also significantly associated with AF 
score. Individuals aged 80 years and over were associated with poorer performance on the AF, 
conversely, younger age participants were associated with better performance on the AF. All ethnic 
groups were negatively associated with poorer performance on the AF. Individuals with low level 
education were negatively associated with poorer performance on the AF as well. 
2.5.3 Multiple Linear Regression 
Tables 9-11 (S1 Appendix) represent a multiple linear regression analysis to evaluate the 
relationship between each of urinary PAH metabolites group and DSST test score adjusted for all 
covariates (age, gender, race and ethnicity, annual family income, smoking and alcohol status, and 
other covariates). 
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There is a significant negative association between each of the total urinary PAH 
metabolites, as well as with NFP urinary metabolites, and DSST score (p-value 0.04 for each mod-
el). For every 1 percent increase in logarithm of PAH-total and PAH (NFP), there was a significant 
decrease of 0.88% in DSST score after adjusting for age, gender, race and ethnicity, annual family 
income, smoking and alcohol status, and other covariates. The same was true for 1-OHPyr in urine 
(Table 11), where there was a significant negative association between 1-OHPyr and DSST score 
(p-value 0.04).) For every 1 percent increase in logarithm of 1-OHPyr, there was a significant 
decrease of 1.64% in DSST score after adjusting for age, gender, race and ethnicity, annual family 
income, smoking and alcohol status, and other covariates.  
Urinary creatinine was examined as a potential confounder in linear regression models to 
adjust for urinary dilution of PAH and metabolites. However, urinary creatinine was not a 
significant predictor and was not significant in final models. Thus, it was not added to the modeling 
since its addition did not change the root mean squared error for the biomarkers of total PAH, NFPs, 
and 1-OHPyr models, respectively. 
Tables 12-14 (S1 Appendix) represent a multiple linear regression analysis to evaluate the 
relationship between each urinary PAH metabolites group and DWR test score adjusted for all 
covariates (age, gen-der, race and ethnicity, annual family income, smoking and alcohol status, and 
other co-variates). 
There was a significant negative association between each of total urinary PAH metabolites, 
NFP urinary metabolites, and DWR score (p-value 0.04 for both models). For every 1 percent 
increase in logarithm of PAH-total and PAH (NFP), there was a significant decrease of 0.12% in 
DWR score after adjusting for age and the medical condition of coronary heart disease. Conversely 
for 1-OHPyr in urine (Table 14), there was a significant positive association between urinary 1-
OHPyr metabolite and DWR score (p<0.05). For every 1 percent increase in logarithm of 1-OHPyr, 
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there was a significant increase of 0.23% in DWR score after adjusting for age, gender, race and 
ethnicity, education level, smoking status, and other covariates. 
Tables 15-16 (S1 Appendix) represent a multiple linear regression analysis to evaluate the 
relationship between urinary PAH metabolites group and WL test score adjusted for only (age, 
diabetes, and coronary heart disease covariates). 
As shown in Tables 15 and 16, there is a significant negative association between each of 
total urinary PAH metabolites, NFP urinary metabolites, and WL score (p-value 0.03 for both 
models. For every 1 percent increase in logarithm of PAH-total and PAH (NFP), there is a 
significant decrease of 0.27% in WL score after adjusting for age, diabetes, and coronary heart 
disease covariates. 
Tables 17-18 (S1 Appendix) represent a multiple linear regression analysis to evaluate the 
relationship between urinary PAH metabolites group and AF test score adjusted for age, annual 
income, alcohol consumptions, kidneys problems, and physical activities.  
As shown in Tables 17 and 18, there is a significant negative association between each of 
total urinary PAH metabolites, NFP urinary metabolites, and AF score (p-value 0.04 for both 
models. For every 1 percent increase in logarithm of PAH-total and PAH (NFP), there is a 
significant decrease of 0.39% in AF score after adjusting for age, annual income, alcohol 




Our study used NHANES data collected from 2011-2014 to examine the association 
between urinary PAH metabolites and each of DSST, DWR, WL, and AF scores for cognitive 
function among adult US residents. Our main findings were that overall males, Blacks, people with 
lower education level (less than high school), people with low income, and people who are 
considered smokers were more exposed to PAH. Also, males, the oldest age group (80 years and 
over), Hispanics and Blacks, people with lower education level (less than high school), individuals 
with low income, and smokers had lower scores for all cognitive tests.  
Our socio-economic status results were similar to previous reports that found an association 
between socio-economic status and poor performance in cognitive test scores among adults 
(Millán-Calenti et al., 2009; Wee et al., 2012; Wu et al., 2016). A study conducted in Portugal 
among individuals aged 50 years and over found a positive association between age and cognitive 
decline, the study stated that with increasing age, the number of people with cognitive impairment 
was increased as well (Paúl, Ribeiro, and Santos 2010). Xu et al. (2015) found that low income or 
poor financial status had an association with cognitive decline among adults aged 65 years and 
older. Another study that was conducted in Taiwan among individuals aged 65 years and over 
found that low education, history of medical condition, such as stroke, poor physical activity and 
physical function had an association with a higher risk of cognitive impairment (Wu et al., 2011). 
Having a lower education level may affect cognitive function among adults, and that could be 
explained by the fact that individuals who are well educated may have a larger brain reserve 
capacity than people with less education (Schmand et al., 1997). It has been suggested that highly 
educated people are more used to searching more during their school life, which may enhance their 
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mental stimulation, and consequently affects the brain function and its structure (Beydoun et al., 
2014). 
2.6.1 DSST 
Our findings showed a negative association between all urinary PAH metabolites groups 
and measures of DSST scores. Our results showed that DSST scores were lower by 1.93–2.81 
points per one unit increase in log-transformed PAH metabolite levels, and lower by 0.88-1.64 
points per one unit increase in log-transformed PAH metabolite levels when adjusted for other 
covariates. These results confirm the trend presented by previous studies. Best et al. (2016) found 
a negative association between each of log-transformed urinary PAH metabolites (total PAH, PAH 
(NFP), 1-hydroxypyrene) and DSST scores. They also found that DSST scores were lower by 1.93–
2.03 points per one unit increase in log-transformed PAH metabolite levels. However, they only 
found a negative association between urinary log-transformed for 1-hydroxypyrene metabolite 
adjusted with other co-variates and DSST score, which was lower by 1.81 points per one unit 
increase in log-transformed PAH metabolite levels. 
Regarding ethnicity and race, our study shows that the highest prevalence of PAH expo-
sure, as well as the lowest test scores, was among individuals Blacks and Hispanic groups for both 
unadjusted and adjusted models. These results could be explained by the role of the interaction 
between the exposure to PAH and DNA Adducts during pregnancy. According to Wang et al. 
(2008), their study mentioned that there is an interaction effects between PAH exposure and genetic 
markers in Blacks and Dominicans (Hispanic) population, they illustrated that maternal adducts 
were higher in mothers with homozygous wild-type GG within the high PAH exposure group in 
Black. They also found that maternal adducts were higher in mothers with homozygous wild-type 
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CC within the high PAH exposure group among Dominican people. This PAH-DNA interaction 
may affect the CP among these ethnic groups particularly with increasing age (Wang et al., 2008). 
Moreover, individuals who smoke have the highest prevalence of urinary PAH biomarkers 
concentration, as well as have lower DSST scores comparing to non-smokers. In fact, smoking 
status was also significantly associated with DSST score (P=0.01). We found that smokers have 
lower DSST scores than non-smokers by 3.57 points. We also found in adjusted models that per 
one unit increase in each of log-transformed for total PAH, PAH (NFP), and 1-hydroxypyrene 
metabolites levels, smokers had lower DSST scores than non-smokers by 3,83, 3,83, 3.05, 
respectively.  
Our results for the exposure to PAH metabolites and DSST scores among smokers was 
similar to Akhtar`s et al (2013) results, they found that among former smokers, the DSST scores 
were lower by 0.91–0.93 points per one unit increase in log-transformed PAH metabolite levels. 
Akhtar et al used blood cotinine (a metabolite of nicotine) concentrations as a predictor variable. 
Since we found that self-reported smoking status was a significant predictor in our analysis and 
thus did not incorporate cotinine, the more specific marker of smoking into our models. In addition 
to being a marker of smoking status, cotinine levels reflect the internal dose of nicotine from 
tobacco smoke. In our analysis, we found overall the highest smoking rate was among white 
participants although blacks and Hispanics had worse PAH and test scores, which would suggest 
additional PAH exposure that is beyond the PAH in tobacco smoke. Our results for smoking and 
racial disparities are similar to Nguyen et al (2020) results, in their comprehensive cohort study 
that sought to examine the racial disparities and the exposure to different chemical biomarker 
concentrations, including cotinine among United States women, they found that Non-Hispanic 
white women had the highest cotinine levels compared to Mexican-American and other Hispanic 
women (Nguyen et al 2020).  
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Moreover, an overview study that sought to understanding nicotine effects on cognitive 
function using preclinical models and human studies reported that the worse performance on some 
cognitive functions, such as working memory task, impaired response inhibition, and motor 
impulsivity were found among smokers (Valentine and Sofuoglu, 2018). 
2.6.2 DWR 
To the best of our knowledge, this is the first report that examined the association between 
PAH exposure and neuropsychological tests measurement using other cognitive function tests other 
than the DSST.  
There was no association between any of urinary PAH metabolites groups and measures of 
DWR scores. We found a negative association between each of log-transformed of total urinary 
PAH and log-transformed of PAH (NFP) metabolites and measures of DWR scores only after 
adjusting for age and the medical condition of coronary heart disease variables (P=0.04). DWR 
scores were lower by 0.12 points per one unit increase in each of log-transformed of total PAH and 
log-transformed of PAH (NFP) metabolites.  
This relationship between age and DWR test performance was most pronounced in the elder 
age group of 80 years and over. The elder group had lower DWR scores that were 1.53 points lower 
than the 70-79 age group and 2.23 points lower than the 60-69 age group per one unit increase in 
each of log-transformed of total PAH and log-transformed of PAH (NFP) metabolites. Our results 
suggest that the exposure to PAH can worsen the memory function among older adults. A recent 
study conducted on rats stated that the exposure to B[a]P at early gestation causes learning and 
memory deficit in offspring rats affecting the neuronal survival in their later-life (Das, Patel, and 
Patri, 2019).  The study found a significant reduction of hippocampal neurons and glial cells after 
47 
exposure to B[a]P at early gestation when compared with control group and possibly show how 
PAH exposure might affect learning and memory over life-time. However, further research is 
needed to determine how these results translate to human exposures and to determine the molecular 
mechanisms and the cellular interactions underlying PAH altered learning and memory in adults. 
There was a positive association between coronary heart disease and DWR test 
performance. Individuals with coronary heart disease had lower DWR scores than individuals who 
do not by a 1.18 per one unit increase in each of log-transformed of total PAH and log-transformed 
of PAH (NFP) metabolites. There are many studies that found a decline in cognition, especially in 
executive function domain, among patients with heart diseases (Burkauskas et al. 2018; Eggermont 
et al., 2012; Burstyn et al., 2005). Our results suggest that adding the factor of the exposure to PAH 
would further increase the risk of cognitive decline among patients with heart diseases. 
2.6.3 WL 
There was no association between any of urinary PAH metabolites groups and measures of 
WL scores. We only found a negative association between each of log-transformed of total urinary 
PAH and log-transformed of PAH (NFP) metabolites and measures of WL scores after adjusting 
for age, diabetes, and coronary heart disease variables (P=0.03). WL scores were lower by 0.27 
points per one unit increase in each of log-transformed of total PAH and log-transformed of PAH 
(NFP) metabolites. 
There was a positive association between diabetes and WL test performance (p<.0001), 
individuals with diabetes had lower WL scores compared to individuals with no diabetes by 1.03 
per one unit increase in each of log-transformed of total PAH and log-transformed of PAH (NFP) 
metabolites. Different studies concluded that diabetes mellitus type 1 and type 2 have been 
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associated with reduced performance on different domains of cognitive function, insulin resistance, 
vascular disease hyperglycemia, and hypoglycemia may play roles of the pathophysiology of 
cognitive dysfunction in diabetic patients (Kodl and Seaquist, 2008).  
Type 2 diabetes may affect and decrease each of psychomotor speed, executive function, 
and verbal memory (Gregg et al., 2000; Reaven et al., 1999). In fact, type 2 diabetes may increase 
the incidence of Alzheimer’s disease and vascular dementia (Cukierman, Gerstein, and 
Williamson, 2005; Luchsinger et al., 2001). According to Bruce et al. (2003), about 11 % of elderly 
patients with type 2 diabetes had cognitive impairment, and 14 % had depression which have a 
negative effect on both of cognitive function and daily activities (Bruse et al., 2003). 
2.6.4 AF 
There is a negative association between urinary PAH metabolites groups (PAH total and 
PAH [NFP]) and measures of AF scores for both unadjusted and adjusted models. Our results 
exhibit that AF scores were lower by almost 0.43 points per one unit increase in log-transformed 
PAH metabolite levels, and lower by 0.39 points per one unit increase in log-transformed PAH 
metabolite levels when adjusted for other covariates. 
There was association between kidney problems and AF test performance, individuals with 
kidney problems had lower AF scores than individuals who do not have kidney problems by 1.77 
per one unit increase in each of log-transformed of total PAH and log-transformed of PAH (NFP) 
metabolites. Chronic kidney disease (CKD) almost affects 45% of adults aged 70 years and older 
in the United States (Coresh et al., 2007). In general, patients with CKD may have large and small 
blood vessel disease, which may cause white matter disease, reduction and impairment in white 
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matter lead to poor physical function, vascular dysfunction, cognitive decline and other 
neurodegenerative diseases (Lau, Huisa, and Fisher, 2017; Bronas, Puzantian, and Hannan, 2017).  
There was a negative association between physical activities and AF test performance, 
individuals who do not practice any physical activities had lower AF scores than individuals who 
practice any physical activities by 3.55 per one unit increase in each of log-transformed of total 
PAH and log-transformed of PAH (NFP) metabolites. A study stated that practicing physical 
activities may improve and enhance the cognitive function in older adults with mild cognitive 
impairment, the study involved 170 elderly persons asked to begin a 24-week physical exercise 
program (home-based), when the physical exercise program finished (after 6 months), the study 
found an improvement in the intervention among the group, especially for episodic memory, 







3.0 The Effect of Polycyclic Aromatic Hydrocarbons Exposure on Hypertension by Race in 
the United States Older Adults (National Health and Nutrition Examination Survey: 2011-
2014) 
In preparation for submission 
3.1 Introduction 
There is substantial epidemiological evidence that elevated blood pressure, hypertension 
(HTN), is a major risk factor for cardiovascular disease (CVD), the leading cause of death in 
worldwide (WHO, 2004; Bangia et al., 2021; Abboud and Karam, 2021; Aryal, Harmon, and 
Dugas, 2021). The general consensus indicates that elevations of 5 mmHg systolic blood pressure 
(BP) and 10 mmHg diastolic BP are associated with increase the risk of CVD (Brook and 
Rajagopalan, 2009). For most individuals, HTN presents as asymptomatic, yet consequences of 
sustained HTN increase CVD morbidity and mortality if not diagnosed early and treated with 
proper HTN medications (Aranda, Calderon, and Aranda, 2008).  
HTN is a multifaceted disease or syndrome that is often of unknown etiology. Multiple 
factors, including the environmental airborne pollutants particulate matter (PM) and ozone 
(Aryal, Harmon, and Dugas, 2021; Kreutz et al., 2021; Giorgini et al., 2010) are known to affect 
development of HTN disease. PAH from the environment or tobacco smoking constitute another 
modifiable exposure that can increase the risk of HTN (Abboud and Karam, 2021; Sancini et al., 
2014; Zhang et al., 2021; Shiue, 2015). 
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PAH are chemical constituents of PM that are generated by incomplete combustion of 
organic materials, such as coal, oil, gas, exhaust fumes, garbage, and tobacco (National 
Toxicology Program, 2014). They are mixtures of hazardous toxic and genotoxic compounds that 
are highly dispersed in the environment (air, soil and water) (Polanska et al., 2014). PAH are 
considered as a significant public health concern as exposure to PAH, whether acutely or 
chronically may increase the risk of human diseases, including cardiovascular and lung diseases, 
as well as cancers (Polanska et al., 2014). According to International Agency for Research on 
Cancer (IARC) 2010, the PAH are carcinogenic compounds consisting of carbon and hydrogen 
that form two to six fused aromatic rings structures. 
PAH are released from different sources, including natural resources, such as volcanic 
eruptions or forest fires (Ramesh et al., 2004). However, the major source of PAH is 
anthropogenic, especially from human and industrial activities that include burning of fossil fuels, 
transportation, fumes released from manufacturing industries, and smoking (Ramesh et al., 2004) 
There are different ways to estimate the internal dose of PAH exposure. This includes 
biomonitoring of PAH concentrations in urine, which is a marker of current exposure as urinary 
PAH metabolites can be eliminated from the body within one day (half-life of <35hours) (Li et 
al., 2010). 
The link between air pollutants and the risk of cardiovascular diseases, including HTN has 
been well investigated in recent studies (Lee, Kim, and Lee, 2014; Tibuakuu et al., 2018; 
Burroughs and Rollins, 2017; Baccarelli and Ghosh, 2012). However, limited studies have 
examined the effect of PAH on HTN risk by race among older adults. 
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3.2 Hypothesis and Aims 
 
We hypothesize that the effect of PAH exposure on HTN may change by race among 
older adults. Most studies have focused on addressing the relationship between PAH and HTN. 
However, there are knowledge gaps regarding understanding the impacts of PAH on HTN by race 
and ethnicity among older adults. One study conducted over a period of two years (2011-2012) 
found an association between PAH exposure and HTN among older adults (Shiue, 2015), 
however, the study did not examine whether that association would differ by race and ethnicity. 
To expand on the previous findings, we examined HTN incidence over four years (2011-2014) in 
a cohort of older adults combined with a battery of urinary PAH biomarkers (1- and 2-
hydroxynaphthalene (1-OHN and 2-OHN), 2- and 3-hydroxyfluorene (2-OHFl, 3-OHFl), 1-, 2-, 
and 3-hydroxyphenanthrene (1-OHPhe, 2-OHPhe, 3-OHPhe), and 1-hydroxypyrene (1-OHPyr)) 
to determine associations between HTN and PAH exposure. This allowed stratification of 
exposures and clinical outcomes on the basis of race and ethnicity. 
3.3 Materials and Methods 
3.3.1 Study population and data collection 
The study cohort consisted of 3,181 adult survey participants. Surprisingly, 3059 of the 
participants had HTN, but only 988 of these participants had both HTN and urinary PAH measures. 
Only 122 participants did not have HTN (non-HTN), and only 50 of these participants had both 
non-HTN and urinary PAH measures (Figure 13). 
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Data were obtained from National Health and Nutrition Examination Survey (NHANES) 
for the years 2011-2014. NHANES is a series of cross-sectional surveys conducted by the National 
Center for Health Statistics (NCHS), which is part of the Centers for Disease Control and 
Prevention (CDC). The data survey analysis for this study consists of household interviews and 
physical examinations performed in a mobile examination center (MEC). Eligible individuals 
included all adults aged 60 years and over with urinary PAH metabolite measurements. 
 
Figure 13 The total number of NHANES HTN and non-HTN participants, with urinary PAH biomarkers 
measured  
Blood pressure assessment was obtained from NHANES surveys during household 
interviews for the period of 2011 to 2012 and for 2013 to 2014.  
3.3.1.1 Urinary biomarkers of PAH  
Urine samples were collected from participants at MEC, the samples were stored under low 
temperature (–20°C), and sent to National Center for Environmental Health for farther analysis 
(CDC, 2014b; CDC, 2016). The analysis procedure included enzymatic hydrolysis of 
glucuronidated/sulfated OH-PAH metabolites in urine to remove PAH conjugates, extraction 
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including mono-hydroxylated PAH metabolites. The urinary metabolites were analyzed using 
isotope dilution capillary gas chromatography with high-resolution mass spectrometry (GC-
MS/MS) (CDC, 2014b; CDC, 2016). Some of PAH metabolites results were below the lower limit 
of detection (LLOD), for that reason, a value was imputed as a lower limit of detection divided by 
square root of 2 (CDC, 2014b; CDC, 2016). 
For this study, urinary PAH biomarkers were: 
1-OHN and 2-OHN,  
2-OHFl and 3-OHFl 
1-OHPhe, 2-OHPhe, and 3-OHPhe 
1-OHPyr 
Measure of urinary creatinine was added as a potential confounder in regression models to 
account for PAH biomarker variation due to differences in urine dilution. Each urinary PAH 
biomarker group was used as predictor for HTN in logistic regression model. To satisfying 
normality assumptions, we took the natural logarithmic transformation of each PAH metabolite 
measures for all statistical analyses.  
3.3.1.2 Socio-demographic variables, risk factors, and confounders  
Data were used to examine the hypothesis that the PAH biomarkers associated with HTN 
change by race after adjusting for risk factors, such as age, gender, tobacco smoking, alcohol 
consumption, body mass index (BMI), and lack of physical activity. The risk factors, were 
categorized into different groups similarly to earlier studies (Shiue, 2015). 
Racial groups were classified as Hispanic, Asians, Blacks, and Whites. Age at the time of 
screening is categorized into three groups: 60–69, 70–79, and 80 and over. Gender was categorized 
as male or female. Smoking - cigarette use was classified as smoker (individuals who smoked at 
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least 100 cigarettes in entire their lives or non-smoker (smoking less than 100 cigarettes in life) 
(yes/no). Alcohol consumption was categorized into alcohol drinker (drinking more than 12 
alcoholic drinks a year) or non-drinker (drinking less than 12 alcoholic drinks a year) (yes/no). 
BMI is defined as weight in kilograms divided by height in meters squared, this variable was 
categorized into three groups normal (<25), obese (25-29.9), and over weight (=>30). Physical 
activity variable included participants who reported (yes/no) that they practice and engage in daily 
activities, such as walking or using bicycle. Blood pressure was categorized into individuals who 
had HTN (participants take prescribed medicine for hypertension) or Non-HTN, as self-reported 
answers (yes/no).  
The data were exempt from human subjects review as this study used public dataset 
(NHANES 2011-2014) that were anonymized and de-identified before it was analyzed. 
3.4 Statistical Analysis 
Descriptive statistics used to characterize the study participants included counts, means, 
and standard error (SE) for continuous variables, and for counts, percentages (weighted), SE for 
categorical variables. Missing data (N) were not included, since NHANES collected the sample 
data randomly. 
Survey-weight logistic regression analyses were used to measure the association of 
urinary PAH biomarkers with race and HTN presenting with odds ratios (OR) and 
95%confidence intervals (CI). The regression model is: 
y = βo + β1log(X1) + β2 (X2) + β3 (X3) + β4 (X4)………. 
where y is the hypertension status (yes/no), βo is the intercept of the regression line, β1 is 
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coefficient of the regression model that represents the change in the mean of the hypertension 
status for each unit change in the log of a specific PAH biomarker, X1 is the logarithm of a 
specific PAH biomarker, X2 is another covariate to adjust for in the model. 
All data were analyzed using SAS Version 9.4  
3.5 Results 
3.5.1 Descriptive Statistics 
The majority of participants were between 60 and 69 years old (~55%), and there were 
more female participants than male (55% versus 45%) (Table 19) (S1 Appendix). Additionally, 
the percentage of White participants was the highest 78%. Race was significantly associated with 
the total of urinary PAH biomarkers (1-OHN, 2-OHN, 3-OHFl, 2-OHFl, 3-OHPhe, 1-OHPhe, 2-
OHPhe, and 1-OHPyr) (Table 20) (S1 Appendix). The difference in natural log mean of the total 
of urinary PAH biomarkers between blacks and whites was 0.58 ng/L. Also Race and smoking 
were significantly associated with the total of urinary PAH biomarkers after adjusting for the 
other variables (age, gender, alcohol consumption, physical activities, and hypertension (Table 
21) (S1 Appendix), he difference in natural log mean of the total of urinary PAH biomarkers 
between black and white was 0.61 ng/L after adjusting for other variables. 
Table 22 (S1 Appendix) shows the descriptive statistics for HTN participants with urinary 
PAH biomarkers measured by race (categorical) variable. Black individuals had the highest 
urinary PAH biomarkers concentrations (Figure 14).  
Only one urinary PAH biomarker (1-hydroxynaphthalene relative to racial categories was 
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significantly associated with HTN (p<0.0001) adjusting for age, gender, smoking, alcohol 
consumption, BMI, and physical activity status.  
Tables 23-25 (S1 Appendix) demonstrate the probability of developing HTN for 
individuals with different urinary 1-hydroxynaphthalene concentrations by race groups. Overall, 
Blacks with different urinary concentrations (2.5, 5, 7.5 ng/L) of log-1-hydroxynaphthalene 
biomarker had the highest probability (~99%) of developing HTN compared to other race groups. 
Table 26 (S1 Appendix) shows the Odds ratio of developing HTN. Each increase in one 
unit of urinary Log-1-hydroxynaphthalene biomarker is associated with 1.1 greater odds of 
developing HTN among Hispanic, 2.0 among Asians, 0.5 among Blacks, and 1.0 among Whites. 
Figure 15 represents an example of a plot predicted probabilities of developing HTN among 
participants males with urinary 1-hydroxynaphthalene measured, aged 80 years and over, 
smokers, non-consuming alcohol, BMI=>30, and practice physical activities. 
 
 
Figure 14 The geometric means of Log urinary PAH biomarkers concentrations for HTN participants by 
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Figure 15 A plot of predicted probabilities of developing HTN by different racial groups with urinary of 1-
hydroxynaphthalene measured 
3.6 Discussion 
Our study used NHANES data collected from 2011-2014 to examine whether urinary PAH 
biomarkers associated with HTN differ by race in older adults. We found that there was an 
association between only one urinary PAH metabolite (urinary 1-hydroxynaphthalene biomarker) 
relative to race and HTN (p<0.001). Overall, blacks had the highest concentrations of urinary PAH 
metabolites compared to other ethnic groups. Also, overall, Blacks with different urinary 1-
hydroxynaphthalene biomarkers had the highest probability of developing HTN compared to other 
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race groups. Additionally, for each increase in one unit in log-transformed 1-hydroxynaphthalene 
level is associated with greater odds of developing HTN relatively for all races.  
Our results were similar to previous studies that found an association between PAH 
metabolites and HTN. Ranjbar et al. (2015) found an association between different urinary PAH 
biomarkers, such as 2-naphthalene and 2-phenanthrene and HTN, however, there study did not 
include a race as an interaction factor/effect modifier with HTN, instead, they included obesity as 
an effect modifier in HTN among individuals with high concentrations of urinary PAH metabolites. 
Another study found an association between urinary PAH biomarkers and different cardiovascular 
diseases, including HTN (Shiue, 2015). However, the study also did not examine race as an effect 
modifier in HTN.  
Our findings show that black individuals with different urinary 1-hydroxynaphthalene 
biomarker concentrations had the highest probability of developing HTN compared to other race 
groups. Also, the odds of developing HTN for relatively all racial groups was greater for each 
increase in one unit in log-transformed of urinary 1-hydroxynaphthalene biomarker level. This 
effect modification in the association between PAH and blood pressure by race may also reflect 
differences in factors not examined in this study, such as gene-environment interactions or 
nutrition-environment interactions (Song et al., 2010). 
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4.0 Conclusions and Future Directions 
We conclude that there was a significant negative association between PAH metabolites 
and CP in older adults. The highest associations between PAH and lowest CP were among males, 
Blacks and Hispanics, individuals with lower education level, individuals with low income, and 
individuals who are considered smokers. In addition, the oldest age group of 80 years and over had 
the lowest CP. DSST was the most sensitive test of detections the CP among older adults. Lastly, 
Urinary 1-OHPyr metabolite had a strong negative association with CP in older adults.  
We also conclude that there was a significant association between urinary 1-
hydroxynaphthalene biomarker relative to race and HTN in older adults. For each increase in one 
unit in log-transformed of 1-hydroxynaphthalene level was associated with greater odds of 
developing HTN relatively for all race groups. Additionally, higher urinary concentrations of 1-
hydroxynaphthalene biomarker were among Blacks comparing to other ethnic groups. Black 
individuals with different urinary 1-hydroxynaphthalene biomarker concentrations also had the 
highest probability of developing HTN compared to other race groups.  
The findings of our study may be used to increase the awareness of exposure impacts among 
the highest risk groups. Also, the translation of our results would be a great step to residents, 
stakeholder, and policy makers to prevent and mitigate air pollution resources 
 Our findings among minorities and vulnerable populations confirm the trend presented by 
previous studies. Different research studies and reports attempted to observe the linkages between 
PAH exposure and different diseases in environmental justice neighborhoods. For instance, a recent 
study showed that in eastern Houston (the Houston Ship Channel) in Manchester, Texas, where the 
most population are Hispanic neighborhoods had medical conditions related to environmental 
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justice communities including chronic exposure to air pollution, the study reported that these 
communities are at high risk of hazardous substances exposure, for instance, within 1 mile of these 
neighborhoods, there are 21 facilities that report to the EPA’s Toxic Release Inventory, such as 4 
facilities that dispose hazardous wastes and about 9 major air pollution dischargers. (Chakraborty 
et al., 2014; Sansom et al., 2018). 
public health efforts should work to create new plans, policies, and regulations that help to 
mitigate the release of PAH into the atmosphere. In addition, the efforts should seek an effective 
treatment for cognitive impairment. 
4.1 Limitations and Strengths 
The limitations of our study include the sample selection, which omitted people with 
missing data. The survey for the cognitive tests does not include all components/domains of 
cognition. Individuals who perform well in one domain may not perform well in another domain. 
Most of cognitive measurements, cognitive assessments, and cardiovascular diseases assessments, 
including blood pressure were performed as self-reported binary questions. This kind of survey 
cannot replace a clinical diagnose for cognitive disorders or for hypertension. The genotypic data 
of the study group that may link to cognitive decline were not available. In addition, PAH 
metabolites are eliminated from the body with a half-life of <35 hours, and thus the urinary PAH 
measurements may not represent chronic or long-term exposures. There was a small number of 
non-HTN participants with PAH measures (the control group), therefore, if the number was larger, 
the outcomes might be different. 
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The strengths of our study are that cognitive assessments and cardiovascular diseases 
assessments were administered in private examination centers, which were more similar clinical 
than household settings. In addition, we used urinary PAH concentrations in our analysis rather 
than using the PAH-air pollution exposures as an aggregated measurement from environmental 
monitoring. The large sample size of older adults, the use of generalizable NHANES data, and use 
of biomarkers of specific chemical groups added to the significance of our results. 
4.2 Future Directions, Guidelines and Regulations of PAH Exposure 
Our findings would enhance public health efforts to combat against PAH emission, 
especially among minorities. Public health has taken different approaches to reduce PAH exposure, 
for instance, cigarette smoke is an important source of PAH emission and exposure at the same 
time, therefore, different efforts, such as awareness campaigns were conducted to stop this negative 
behavior for reducing PAH exposure among smokers and second-hand smokers (ATSDR, 2009a). 
Also, different efforts were taken to recommend individuals to avoid the exposure to PAH, for 
instance, wearing gloves when working with cutting oils or any other substances that include PAH, 
and avoiding burning practices that increase the PAH release to the atmosphere (ATSDR, 2009a).  
Our finding may also increase the awareness among minorities, the need for new polices 
and regulation should be implemented to reduce the emission of PAH, and the exposure among 
vulnerable ethnic groups, consequently, different United Stated agencies established standards 
concentration limits for PAH in the environment and in the workplace. For instance, Occupational 
Safety and Health Administration (OSHA) air contaminants standard established specific standard 
limits for PAH substances, such as coal tar pitch volatiles (CTPVs) and coke oven emissions which 
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is covered by the coke oven emissions standard (ATSDR, 2009a). OSHA requires from employers 
to control employee exposure to coke oven emissions by using different engineering controls and 
work practices, employers should use engineering controls and work practices to reduce employee 
exposures to the lowest level achievable, as well as using supplemental engineering controls like 
respiratory protection procedures (ATSDR, 2009a). The OSHA permissible exposure limit (PEL) 
for PAH exposure in the workplace is 0.2 milligram/cubic meter (mg/m3) (Table 27) (S1 
Appendix).  
4.2.1 Future Directions, Policies and Regulations of Cognitive Impairment 
According to the CDC report (2011), about more than 16 million people in the United States 
have cognitive impairment disorders. Because of the increasing number of people living with 
cognitive impairment, and the cost of cognitive impairment treatment, different efforts and steps 
should be taken to maintain effective policies and programs to address the needs of people living 
with cognitive impairment (CDC, 2011).  
To understand the needs of individuals with cognitive impairment, states, local agencies, 
and different health departments can gather more clinical data related to patients with cognitive 
impairment to understand the impact, burden, and their special needs, which may help to determine 
which age group that should be focus on for treatment more than others (CDC, 2011). 
State agencies, private and public organizations can also develop comprehensive plans that 
can respond to the needs of individuals with cognitive impairment. Also, medical, public health, 
and comprehensive systems should be developed by supporting individuals with cognitive 
impairment, their families, and caregivers (CDC, 2011).  
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Finally, it is recommended to have extra training for health professionals, such as doctors, 
nurses and other health providers to find and detect cognitive impairment especially in early stages, 
and help patients with different health conditions to manage their care (CDC, 2011). 
Further studies should be conducted on this topic, to better define the influence of the 
confounding variables, such as the genetic variability of the enzymes involved in the 
biotransformation of PAH. 
4.3 Cognitive Impairment and Methods of Treatment 
There are extensive efforts to find a treatment for cognitive impairment as well as for both 
Alzheimer`s disease and dementia. However, there are still limitations and challenges involved in 
the treatment process, such as the efficacy for treatment plans. This is especially true for long-term, 
the side effect of medications, the cost of the treatment, and other challenges (Mehlman, 2004). 
Cognitive impairment treatment may include pharmacological or non-pharmacological options, or 
maybe both combined for special treatment plan (University Health System, 2012).  
Lifestyle modifications are an important factor that play a significant role in enhancing 
cogitation performance. For instance, engaging and practicing in daily physical activities, walking 
running, cycling, swimming, and hiking are all examples of practicing physical activities that may 
promote and activate memory functions. A caveat is that increased physical activity in 
contaminated environments can increase exposures and consequently disease risk. In addition, 
activities like socialization may also improve mood and increase quality of life among older adults 
with cognitive disorders (University Health System, 2012).  
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Regarding pharmacological options, the FDA has approved different drugs for treating 
dementia and these drugs improve and enhance the CP among patients with different cognitive 
deficits types (Mehlman, 2004). (Table 28) (S1 Appendix) summarizes an example of some 
medications and the appropriate dose intake per mg daily for patients with dementia (University 
Health System, 2012).  
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Appendix A Supporting Data 
Appendix A.1 includes outcome of statistical analysis for urinary PAH metabolites and each 
of DSST, DWR, WL, and AF tests and other covariates.  
Appendix A.1  Tables 
Table 1 Characteristics of 2011-2014 NHANES participants  
Characteristic N Percent 
(weighted) 
SE 
Total  3,181   
Age     
60-69 1671 54.67 1.19 
70-79 950 29.53 1.04 
80+ 560 15.79 0.73 
Gender    
Male 1547 45.32 1.23 
Female 1634 54.67 1.23 
Race     
Hispanic 615 7.50 0.34 
Whites   1470 78.23 0.71 
Blacks   779 8.98 0.38 
Asians 317 5.27 0.42 
Education level    
Less than high school 875 17.30 0.77 
High school graduate or GED 732 22.18 1.01 
Some college 868 30.82 1.14 
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College graduate or higher 702 29.64 1.18 
Annual family income    
<$25000 1077 25.31 0.96 
$25000 to <$55000 882 30.71 1.16 
$55000+ 957 43.96 1.30 
Smoking Status (Self-reported)    
Smoker 1601 50.26 1.23 
Non-Smoker 1577 49.73 1.23 
Alcohol consumption (Self-reported)    
Yes 171 5.81 0.57 
No 2997 94.18 0.57 
Diabetes (Self-reported)    
Yes 766 19.79 0.92 
No 2268 75.93 1.00 
Medical conditions (Self-reported)    
Congestive heart failure     
Yes 232 7.08 0.58 
No 2934 92.91 0.58 
Coronary heart disease     
Yes 290 9.44 0.68 
No 2891 90.55 0.68 
Angina/angina pectoris     
Yes 171 5.81 0.57 
No 2997 94.18 0.57 
Heart attack     
Yes 278 8.69 0.66 
No 2899 91.30 0.66 
Stroke     
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Yes 246 6.95 0.57 
No 2929 93.04 0.57 
Emphysema     
Yes 116 4.60 0.52 
No 3060 95.39 0.52 
Memory and thinking problems     
Yes 493 13.53 0.76 
No 2686 86.46 0.76 
Kidneys problems (Self-reported)    
Yes 197 4.89 0.45 
No 2980 95.10 0.45 
Physical Activity (Self-reported)    
Vigorous work activity     
Yes 320 12.40 0.88 
no 2860 87.56 0.88 
Walk or bicycle     
Yes 666 18.98 0.98 
No 2515 81.01 0.98 
Vigorous recreational activities  
 
   
Yes 278 10.90 0.84 
No 2903 89.09 0.84 
Physical functioning limitation (Self-
reported) 
   
Limitations that keeps individual from 
working  
   
Yes 674 16.49 0.82 
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No 2506 83.49 0.82 
Limitation in amounts work that 
individual can do  
   
Yes 1044 28.81 1.06 
No 2134 71.12 1.06 
Experience confusion/memory problems     
Yes 425 10.02 0.62 
No 2754 89.92 0.62 
Body Mass Index (BMI)    
<25 844 26.17 1.08 
25-29.9 1091 36.03 1.19 
=>30 1184 37.78 1.20 
Hypertension (Self-reported)    
HTN 3059 96.54 0.42 
Non-HTN 122 3.45 0.42 
Cholesterolemia (Self-reported)    
Yes 1589 53.69 1.27 
No 1344 46.30 1.27 
N- number 
SE—standard error 
mg/dL—milligrams per deciliter 
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Table 2 Means and standard errors for continuous variables  
Characteristic N Mean (SE) 95% CI 
Total 3181   
DSST total scores 3011 51.86 (0.40) (51.06, 52.66) 
WDR total scores 3126 6.13 (0.05) (6.02, 6.24) 
WL total scores 3126 19.49 (0.10) (19.28, 19.71) 
AF total scores 3102 17.89 (0.14) (17.61, 18.17) 
DSST- Digit symbol substitution test  
DWR- Delayed Word Recall test 
WL- Word list learning 






Table 3 Means and standard errors for urinary PAH biomarkers 
Characteristic N Mean SE 95% CI 
PAH-total metabolites1 (ng/L) 1013 55387 18936 (18000, 92000) 
PAH-smaller molecular metabolites1 (ng/L) 1013 55250 18936 (18000, 92000) 
1-OHPyr1 (ng/L) 1013 137.26 10.61 (116, 158) 
Urinary creatinine1 (ng/L) 1031 96.24 2.53 (91, 101) 
1 Geometric means 




Table 4 Characteristics of 2011-2014 NHANES participants for categorical variables by urinary PAH 


























Age          
60-69 6247.5 (1.1) 6120.2 (1.1) 90.1 (1.1) 75.8 (1.0) 56.4 (1.0) 6.7 (0.1) 20.8 (0.2) 19.6 (0.4) 
70-79 6020.9 (1.1) 5885.8 (1.1) 81.1 (1.1) 80.4 (1.0) 48.5 (1.0) 6.0 (0.2) 18.8 (0.3) 16.9 (0.4) 
80+ 5781.6 (1.1) 5659.9 (1.1) 63.9 (1.1) 77.6 (1.1) 38.9 (1.2) 4.4 (0.2) 16.5 (0.5) 13.7 (0.4) 
Gender         
Male 6877.1 (1.1) 6729.4 (1.1) 95.0 (1.1) 98.6 (1.0) 49.0 (1.0) 5.7 (0.2) 18.6 (0.3) 18.4 (0.4) 
Female 5522.0 (1.1) 5406.7 (1.1) 74.0 (1.0) 63.9 (1.0) 53.4 (1.0) 6.5 (0.1) 20.3 (0.2) 17.4 (0.4) 
Race          
Hispanic 6796.8 (1.1) 6645.1 (1.1) 90.4 (1.1) 77.6 (1.1) 36.9 (1.3) 5.2 (0.2) 17.3 (0.3) 15.2 (0.4) 
Whites  5653.6 (1.1) 5531.5 (1.1) 79.6 (1.0) 75.5 (1.0) 54.0 (0.9) 6.3 (0.1) 19.8 (0.2) 18.6 (0.3) 
Blacks   10178.7 (1.1) 10018.0 
(1.1) 
102.7 (1.1) 104.9 (1.0) 40.7 (1.1) 5.8 (0.2) 19.4 (0.3) 15.0 (0.4) 
Asian 7003.2 (1.3) 6849.8 (1.3) 94.9 (1.3) 69.8 (1.1) 49.8 (2.3) 6.3 (0.3) 18.3 (0.6) 15.0 (0.4) 
Education 
Level 
        
Less than high 
school 




6040.6 (1.1) 5907.6 (1.1) 77.2 (1.1) 74.2 (1.1) 48.0 (1.4) 5.8 (0.2) 19.2 (0.4) 15.8 (0.4) 




5385.0 (1.1) 5270.3 (1.1) 77.3 (1.1) 76.2 (1.1) 59.0 (1.3) 6.8 (0.2) 20.8 (0.3) 21.2 (0.6) 
Annual family 
income 
        





























6107.1 (1.1) 5985.1 (1.1) 81.4 (1.1) 79.9 (1.1) 49.1 (1.3) 6.0 (0.2) 19.0 (0.3) 17.1 (0.5) 




        
Smoker 6850.0 (1.1) 6706.3 (1.1) 93.3 (1.1) 80.7 (1.0) 49.8 (1.0) 5.9 (0.1) 19.1 (0.2) 18.0 (0.4) 





        
Drinker 6121.6 (1.1) 5984.4 (1.1) 88.4 (1.0) 78.3 (1.0) 53.1 (0.9) 6.3 (0.1) 19.8 (0.2) 18.6 (0.3) 
Non-Drinker 6062.5 (1.1) 5954.3 (1.1) 70.0 (1.1) 75.7 (1.1) 46.9 (1.4) 5.9 (0.2) 18.8 (0.4) 16.0 (0.4) 
Diabetes (Self-
reported) 
        
Yes 6134.7 (1.1) 6020.0 (1.1) 72.5 (1.1) 80.6 (1.1) 43.5 (1.1) 6.0 (0.2) 18.7 (0.4) 16.5 (0.6) 





        
Congestive 
heart failure 
        
Yes 7703.6 (1.3) 7571.3 (1.3) 81.1 (1.2) 83.8 (1.1) 40.6 (2.5) 5.0 (0.4) 17.3 (0.8) 16.1 (0.9) 
No 6005.9 (1.1) 5877.0 (1.1) 83.1 (1.0) 77.2 (1.0) 52.2 (0.8) 6.3 (0.1) 19.7 (0.2) 18.0 (0.3) 
Coronary heart 
disease 
        
Yes 6118.1 (1.2) 5985.7 (1.2) 78.3 (1.1) 83.0 (1.1) 43.4 (1.6) 5.0 (0.3) 17.4 (0.6) 16.1 (0.8) 
No 6104.1 (1.1) 5975.2 (1.1) 83.3 (1.0) 77.1 (1.0) 52.2 (0.8) 6.3 (0.1) 19.7 (0.2) 18.1 (0.3) 
Angina/angina 
pectoris 



























Yes 7010.6 (1.3) 6876.8 (1.3) 88.5 (1.2) 80.0 (1.1) 44.8 (4.0) 5.3 (0.4) 18.7 (0.7) 16.5 (1.0) 
No 6056.1 (1.1) 5927.2 (1.1) 82.6 (1.0) 77.5 (1.0) 51.8 (0.7) 6.2 (0.1) 19.6 (0.2) 18.0 (0.3) 
Heart attack         
Yes 8349.1 (1.2) 8171.1 (1.2) 106.2 (1.2) 87.5 (1.1) 42.9 (1.8) 5.1 (0.4) 17.6 (0.6) 16.0 (0.7) 
No 5905.5 (1.1) 5780.7 (1.1) 80.8 (1.0) 76.6 (1.0) 52.4 (0.8) 6.3 (0.1) 19.7 (0.2) 18.1 (0.3) 
Stroke         
Yes 6998.8 (1.2) 6861.4 (1.2) 75.5 (1.1) 78.9 (1.1) 43.7 (3.0) 5.0 (0.4) 18.0 (0.8) 15.0 (1.0) 
No 6042.7 (1.1) 5914.5 (1.1) 83.0 (1.0) 77.4 (1.0) 51.8 (0.8) 6.2 (0.1) 19.6 (0.2) 18.1 (0.3) 
Emphysema         
Yes 10230.4 (1.3) 10049.1 
(1.4) 
115.3 (1.2) 92.3 (1.1) 45.5 (2.0) 5.2 (0.4) 18.2 (0.7) 16.9 (1.0) 




        
Yes 7414.9 (1.2) 7284.9 (1.2) 74.0 (1.1) 86.1 (1.1) 41.4 (1.7) 4.3 (0.3) 16.3 (0.5) 15.0 (0.6) 





        
Yes 6989.9 (1.2) 6893.2 (1.2) 62.9 (1.1) 79.9 (1.1) 39.9 (1.9) 5.3 (0.3) 17.5 (0.8) 15.9 (0.9) 




        
Vigorous work 
activity 
        
Yes 5519.8 (1.2) 5397.0 (1.2) 86.7 (1.1) 86.2 (1.1) 56.3 (2.0) 6.9 (0.3) 20.7 (0.5) 19.7 (0.7) 





























        
Yes 7128.1 (1.1) 6975.7 (1.1) 101.8 (1.1) 90.0 (1.1) 53.1 (1.7) 6.4 (0.2) 19.7 (0.4) 19.0 (0.6) 




        
Yes 4152.2 (1.1) 4069.2 (1.1) 62.3 (1.2) 73.6 (1.1) 63.2 (2.0) 7.2 (0.3) 21.6 (0.5) 22.5 (1.1) 











        
Yes 8596.0 (1.1) 8449.8 (1.1) 87.5 (1.1) 88.6 (1.1) 40.9 (1.6) 5.2 (0.2) 18.0 (0.5) 15.5 (0.5) 





        
Yes 8550.1 (1.1) 8394.0 (1.1) 87.2 (1.1) 82.5 (1.1) 45.0 (1.4) 5.4 (0.2) 18.5 (0.3) 16.6 (0.4) 




        
Yes 9204.1 (1.2) 9057.9 (1.2) 74.1 (1.1) 85.5 (1.1) 35.3 (1.4) 3.8 (0.3) 15.0 (0.6) 13.0 (0.5) 
No 5844.3 (1.1) 5717.5 (1.1) 83.9 (1.0) 76.7 (1.0) 53.1 (0.8) 6.4 (0.1) 20.0 (0.2) 18.4 (0.3) 
Body Mass 
Index (BMI)  



























<25 5776.8 (1.1) 5657.3 (1.1) 73.4 (1.1) 68.6 (1.1) 52.3 (1.4) 5.9 (0.2) 19.1 (0.4) 17.5 (0.5) 
25-29.9 5737.5 (1.1) 5608.8 (1.1) 85.4 (1.1) 78.7 (1.1) 53.3 (1.2) 6.2 (0.2) 19.6 (0.3) 18.3 (0.5) 





        
HTN 6098.3 (1.1) 5969.5 (1.1) 82.6 (1.0) 77.3 (1.0) 51.4 (0.8) 6.2 (0.1) 19.6 (0.2) 17.9 (0.3) 




        
Yes 6911.0 (1.1) 6771.3 (1.1) 86.2 (1.1) 76.5 (1.0) 50.7 (1.0) 5.9 (0.1) 19.1 (0.3) 17.4 (0.4) 
No 5210.7 (1.1) 5093.7 (1.1) 79.7 (1.1) 78.5 (1.0) 53.4 (1.2) 6.5 (0.1) 20.1 (0.3) 18.7 (0.4) 
1geometric means 
SE- standard error 
GM- geometric mean 
GSE- geometric standard error 
ng/L—nanograms per liter 
mg/dL—milligrams per deciliter 
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Table 5 Univariate model showing association between digit symbol substitution test scores, urinary PAH 
metabolites, and other covariates among 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_Total1 (ng/L) -1.93 (0.56) - <0.0006*
 0.02 
ln_PAH_NFP1 (ng/L) -1.91 (0.55) - <0.0006* 0.02 
ln_1-OHPyr1 (ng/L) -2.81 (0.97) - <0.0038* 0.01 
     
Age   <0.0001* 0.12 
60-69 17.51 (1.62) (14.31, 20.70)   
70-79 9.58 (1.57) (6.50, 12.66)   
80+ - -   
Gender   <0.002* 0.01 
Female 4.41 (1.45) (1.55, 7.27)   
Male -    
Race    <0.0001* 0.10 
Hispanic -17.02 (1.54) -(20.05, 13.99)   
Asians -4.17 (2.42) (-8.93, 0.58)   
Blacks  -13.21 (1.43) -(16.02, 10.40)   
Whites   - -   
Education Level   <0.0001* 0.21 
Less than high school -18.12 (1.74) (-21.54, 14.70)   
High school graduate or GED -6.59 (1.95) (-10.42, -2.75)   
College graduate or higher 4.45 (1.83) (0.85, 8.0424)   
Some college - -   
Annual family income   <0.0001* 0.16 
$55000+ 16.65 (1.70) (13.29, 20.0)   
$25000 to <$55000 6.75 (1.82) (3.18, 10.33)   
<$25000 - -   
Smoking Status (self-
reported) 
  0.01 0.01 
Non-Smoker 3.57 (1.47) (0.68, 6.46)   
Smoker - -   
Alcohol consumption Self-
reported) 
  <0.0001* 0.02 
Drinker 6.23 (1.62) (3.04, 9.42)   
Non-Drinker - -   
Diabetes (Self-reported)   <0.0001* 0.05 
No 9.97 (1.41) (7.20, 12.74)   
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Yes - -   
Medical Conditions Self-
reported 
    
Congestive heart failure   <0.0001* 0.02 
No 11.64 (2.55) (6.62, 16.66)   
Yes - -   
Coronary heart disease   <0.0001* 0.02 
No 8.76 (1.74) (5.34, 12.18)   
Yes - -   
Heart attack   <0.0001* 0.02 
No 9.49 (1.92) (5.71, 13.27)   
Yes - -   
Stroke   <0.0001* 0.01 
No 8.10 (3.06) (2.09, 14.12)   
Yes - -   
Emphysema   <0.002 0.006 
No 6.23 (2.07) (2.15, 10.30)   
Yes - -   
Memory and thinking problems   <0.0001* 0.05 
No 11.68 (1.89) (7.96, 15.40)   
Yes -    
Kidneys Problems   <0.0001* 0.02 
No 12.24 (2.06) (8.18, 16.30)   
Yes - -   
Physical Activity (Self-
reported) 
    
Vigorous work activity   <0.0088 0.01 
No -5.61 (2.13) (-9.80, -1.41)   
Yes - -   
Vigorous recreational activities   <0.0001* 0.05 
No -13.01 (2.12) (-17.18, -8.83)   
Yes - -   
Physical function limitations 
(Self-reported) 
    
Limitations that keeps 
individual from working 
  <0.0001* 0.06 
No 12.48 (1.78) (8.98, 15.97)   
Yes - -   
Limitation in amounts work that 
individual can do 
  <0.0001* 0.05 
No 8.77 (1.62) (5.59, 11.95)   




  <0.0001* 0.09 
No 17.81 (1.58) (14.69, 20.92)   
Yes - -   
1 Log transformed 





Table 6 Univariate model showing association between word delayed recall test scores and other covariates 
among 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
Age   <0.0001* 0.10 
60-69 2.34 (0.25) (1.84, 2.85)   
70-79 1.60 (0.27) (1.07, 2.14)   
80+ - -   
Gender   <0.0001* 0.02 
Female 0.80 (0.20) (0.40, 1.20)   
Male - -   
Race    <0.0001* 0.01 
Hispanic -1.05 (0.21) (-1.47, -0.62)   
Asian -0.02 (0.28) (--0.58, 0.53)   
Blacks   -0.52 (0.20) (-0.92, -0.12)   
Whites   - -   
Education Level   <0.0001* 0.06 
Less than high school -1.33 (0.26) (-1.85, -0.81)   
High school graduate or GED -0.62 (0.28) (-1.18, -0.06)   
College graduate or higher 0.34 (0.27) (-0.18, 0.87)   
Some college - -   
Annual family income   <0.0001* 0.02 
$55000+ 0.88 (0.24) (0.41, 1.36)   
$25000 to <$55000 0.27 (0.25) (-0.21, 0.77)   
<$25000 - -   
Smoking Status (Self-reported)   <0.002* 0.01 
Non-Smoker 0.59 (0.19) (0.20, 0.98)   
Smoker - -   
Medical Conditions Self-
reported 
    
Congestive heart failure   <0.0007* 0.001 
No 1.30 (0.38) (0.55, 2.06)   
Yes - -   
Coronary heart disease   <0.0001* 0.02 
No 1.31 (0.33) (0.65, 1.97)   
Yes - -   
Heart attack   <0.0001* 0.02 
No 1.18 (0.36) (0.46, 1.89)   
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Yes - -   
Stroke   <0.0001* 0.01 
No 1.20 (0.44) (0.32, 2.08)   
Yes - -   
Angina/angina pectoris   0.03 0.006 
No 0.90 (0.43) (0.05, 1.75)   
Yes - -   
Emphysema   0.01 0.008 
No 1.04 (0.43) (0.19, 1.89)   
Yes - -   
Memory and thinking problems   <0.0001* 0.10 
No 2.20 (0.28) (1.64, 2.76)   
Yes - -   
Kidneys Problems   <0.003* 0.008 
No 0.96 (0.33) (0.31, 1.61)   
Yes - -   
Physical Activity (Self-reported)     
Vigorous work activity   <0.003* 0.01 
No -0.80 (0.27) -1.34, -0.25)   
Yes - -   
Vigorous recreational activities   <0.0006* 0.01 
No -1.09 (0.31) (-1.71, -0.46)   
Yes - -   
Physical function limitations 
(Self-reported) 
    
Limitations that keeps individual 
from working 
  <0.0001* 0.02 
No 1.12 (0.26) (0.59, 1.64)   
Yes - -   
Limitation in amounts work that 
individual can do 
  <0.0001* 0.03 
No 0.99 (0.21) (0.57, 1.42)   
Yes - -   
Experience confusion/memory 
problems 
  <0.0001* 0.11 
No 2.67 (0.31) (2.05, 3.28)   
Yes - -   
* p value was significant at 0.05 level 
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Table 7 Univariate model showing association between word list learning test scores and other covariates 
among 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
Age   <0.0001* 0.10 
60-69 4.28 (0.50) (3.29, 5.26)   
70-79 2.29 (0.55) (1.20, 3.39)   
80+ - -   
Gender   <0.0001* 0.03 
Female 1.76 (0.36) (1.04, 2.49)   
Male - -   
Race    <0.0001* 0.02 
Hispanic -2.58 (0.40) (-3.38, -1.77)   
Asians -1.48 (0.62) (-2.70, -0.26)   
Blacks  -0.47 (0.38) (-1.23, 0.28)   
Whites   - -   
Education Level   <0.0001* 0.08 
Less than high school -3.26 (0.47) (-4.20, -2.32)   
High school graduate or GED -0.90 (0.50) (-1.89, 0.09)   
College graduate or higher 0.72 (0.47) (-0.20, 1.65)   
Some college - -   
Annual family income   <0.0001* 0.04 
$55000+ 2.18 (0.44) (1.31, 3.06)   
$25000 to <$55000 0.52 (0.47) (-0.40, 1.45)   
<$25000 - -   
Smoking Status (Self-reported)   0.01 0.008 
Non-Smoker 0.87 (0.36) (0.14, 1.59)   
Smoker - -   
Alcohol consumption (Self-
reported) 
  0.01 0.01 
Drinker 1.06 (0.41) (0.24, 1.87)   
Non-Drinker - -   
Diabetes (Self-reported)   0.04 0.007 
No 1.03 (0.42) (0.19, 1.88)   




    
Congestive heart failure   <0.0004* 0.01 
No 2.42 (0.85) (0.75, 4.09)   
Yes - -   
Coronary heart disease   <0.0001* 0.01 
No 2.29 (0.59) (1.11, 3.46)   
Yes - -   
Heart attack   <0.0001* 0.01 
No 2.09 (0.63) (0.84, 3.33)   
Yes - -   
Memory and thinking problems   <0.0001* 0.08 
No 3.74 (0.56) (2.62, 4.85)   
Yes - -   
Kidneys Problems   <0.008* 0.01 
No 2.11 (0.79) (0.55, 3.67)   
Yes - -   
Physical Activity (Self-reported)     
Vigorous work activity   0.02 0.008 
No -1.28 (0.55) (-2.38, -0.19)   
Yes - -   
Vigorous recreational activities   <0.0001* 0.02 
No -2.29 (0.54) (-3.36, -1.23)   
Yes - -   
Physical function limitations 
(Self-reported) 
    
Limitations that keeps individual 
from working 
  <0.0003* 0.02 
No 1.87 (0.51) (0.86, 2.87)   
Yes - -   
Limitation in amounts work that 
individual can do 
  <0.0001* 0.01 
No 1.42 (0.40) (0.63, 2.22)   
Yes - -   
Experience confusion/memory 
problems 
  <0.0001* 0.10 
No 5.03 (0.64) (3.76, 6.29)   
Yes - -   





Table 8 Univariate model showing Association between animal fluency test scores and other covariates among 
2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_Total1 (ng/L) -0.43 (0.20) - 0.03 0.008 
ln_PAH_NFP1 (ng/L) -0.42 (0.20) - 0.03 0.007 
     
Age   <0.0001* 0.12 
60-69 5.96 (0.54) (4.90, 7.03)   
70-79 3.26 (0.54) (2.18, 4.33)   
80+ - -   
Race    <0.0001* 0.054 
Hispanic -3.42 (0.48) (-4.37, -2.46)   
Asians -3.59 (0.55) (-4.67, -2.51)   
Blacks  -3.56 (0.48) (-4.52, -2.61)   
Whites   - -   
Education Level   <0.0001* 0.17 
Less than high school -3.58 (0.54) (-4.65, -2.50)   
High school graduate or GED -2.14 (0.58) (-3.30, -0.99)   
College graduate or higher 3.20 (0.71) (1.79, 4.60)   
Some college - -   
Annual family income   <0.0001* 0.07 
$55000+ 3.78 (0.62) (2.56, 5.01)   
$25000 to <$55000 0.95 (0.69) (-0.40, 2.30)   
<$25000 - -   
Alcohol consumption Self-
reported) 
  <0.0001* 0.03 
Drinker 2.56 (0.54) (1.49, 3.63)   
Non-Drinker - -   
Diabetes (Self-reported)   0.04 0.01 
No 1.69 (0.67) (0.37, 3.02)   
Yes - -   
Medical Conditions Self-
reported 
    
Congestive heart failure   0.04 0.006 
No 1.89 (0.95) (0.02, 3.76)   
Yes - -   
Coronary heart disease   0.01 0.008 
No 1.95 (0.80) (0.38, 3.53)   
Yes - -   
Heart attack   <0.004* 0.01 
No 2.11 (0.75) (0.64, 3.58)   
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Yes - -   
Stroke   <0.002* 0.01 
No 3.09 (1.02) (1.09, 5.09)   
Yes - -   
Memory and thinking problems   <0.0001* 0.03 
No 3.37 (0.68) (2.03, 4.71)   
Yes - -   
Kidneys Problems   0.03 0.006 
No 2.09 (0.96) (0.19, 3.99)   
Yes - -   
Physical Activity (Self-reported)     
Walk or bicycle   0.04 0.007 
No -1.38 (0.69) (-2.76, -0.01)   
Yes - -   
Vigorous work activity   <0.006* 0.01 
No -2.11 (0.76) (-3.62, -0.60)   
Yes - -   
Vigorous recreational activities   <0.0001* 0.06 
No -5.12 (1.14) (-7.37, -2.87)   
Yes - -   
Physical function limitations 
(Self-reported) 
    
Limitations that keeps individual 
from working 
  <0.0001* 0.02 
No 2.81 (0.60) (1.63, 3.99)   
Yes - -   
Limitation in amounts work that 
individual can do 
  <0.0005* 0.01 
No 1.77 (0.54) (0.70, 2.85)   
Yes - -   
Experience confusion/memory 
problems 
  <0.0001* 0.07 
No 5.46 (0.60) (4.27, 6.65)   
Yes - -   
1 Log transformed 




Table 9 Multivariate model showing association between digit symbol substitution test scores, total PAH in 
urine, and other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_Total1 (ng/L) -0.88 (0.43) (-1.74, -0.03) 0.04 0.48 
     
Age   <0.0001*  
60-69 17.87 (1.55) (14.81, 20.92)   
70-79 9.40 (1.44) (6.57, 12.22)   
80+ - -   
Gender   <0.0001*  
Female 5.94 (1.19) (3.58, 8.29)   
Male -    
Race    <0.0001*  
Hispanic -15.97 (1.62) (-19.15, -12.79)   
Asians -3.37 (2.11) (-7.52, 0.78)   
Blacks  -12.46 (1.29) (-15.00, -9.91)   
Whites   - -   
Annual family income   <0.0001*  
$55000+ 8.65 (1.47) (5.76, 11.55)   
$25000 to <$55000 4.11 (1.39) (1.38, 6.85)   
<$25000 - -   
Smoking Status (self-
reported) 
  <0.0019*  
Non-Smoker 3.83 (1.22) (1.42, 6.24)   
Smoker - -   
Alcohol consumption Self-
reported) 
  <0.0001*  
Drinker 4.44 (1.27) (1.93, 6.94)   
Non-Drinker - -   
Diabetes (Self-reported)   <0.0001*  
No 6.10 (1.36) (3.42, 8.78)   
Yes - -   
Medical Conditions Self-
reported 
    
Congestive heart failure   <0.0013*  
No 5.34 (1.66) (2.09, 8.60)   
Yes - -   
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Memory and thinking 
problems 
  <0.0010*  
No 5.53 (1.68) (2.23, 8.84)   
Yes -    
Kidneys Problems   0.02  
No 4.42 (1.89) (0.69, 8.15)   
Yes - -   
Physical Activity (Self-
reported) 
    
Vigorous recreational 
activities 
  <0.0012*  
No -6.88 (2.11) -(11.03, -2.72)   
Yes - -   
1 Log transformed 
* p value was significant at 0.05 level 
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Table 10 Multivariate model showing association between digit symbol substitution test scores, PAH (NFP) in 
urine, and other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_NFP1 (ng/L) -0.88 (0.43 (-1.73, -0.02) 0.04 0.48 
     
Age   <0.0001*  
60-69 17.87 (1.55) (14.81, 20.92)   
70-79 9.39 (1.44) (6.57, 12.22)   
80+ - -   
Gender   <0.0001*  
Female 5.94 (1.19) (3.58, 8.29)   
Male -    
Race    <0.0001*  
Hispanic -15.97 (1.62) (-19.15, -12.79)   
Asians -3.37 (2.11) (-7.52, 0.78)   
Blacks  -12.46 (1.29) (-15.00, -9.91)   
Whites   - -   
Annual family income   <0.0001*  
$55000+ 8.65 (1.47) (5.76, 11.55)   
$25000 to <$55000 4.11 (1.39) (1.38, 6.85)   
<$25000 - -   
Smoking Status (self-
reported) 
  <0.0019*  
Non-Smoker 3.83 (1.22) (1.42, 6.24)   
Smoker - -   
Alcohol consumption Self-
reported) 
  <0.0005*  
Drinker 4.44 (1.27) (1.93, 6.94)   
Non-Drinker - -   
Diabetes (Self-reported)   <0.0001*  
No 6.10 (1.36) (3.42, 8.78)   
Yes - -   
Medical Conditions Self-
reported 
    
Congestive heart failure   <0.0013*  
No 5.34 (1.66) (2.09, 8.60)   
Yes - -   
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Memory and thinking 
problems 
  <0.0010*  
No 5.53 (1.68) (2.23, 8.84)   
Yes -    
Kidneys Problems   0.02  
No 4.42 (1.90) (0.69, 8.15)   
Yes - -   
Physical Activity (Self-
reported) 
    
Vigorous recreational 
activities 
  <0.0012*  
No -6.88 (2.11) -(11.03, -2.72)   
Yes - -   
1 Log transformed 




Table 11 Multivariate model showing association between digit symbol substitution test scores, 1-
Hydroxypyrene in urine, and other covariates, 2011-2014 NHANES participants 
Variable Estimate (SE)  95% CI P-value R2 
ln_1-OHPyr (ng/L)1 -1.64 (0.80) (-3.21, -0.07) 0.04 0.42 
Age   <0.0001*  
60-69 15.28 (1.72) (11.90, 18.66)   
70-79 9.38 (1.60) (6.22, 12.53)   
80+ - -   
Gender   <0.0001*  
Female 7.50 (1.34) (4.87, 10.13)   
Male -    
Annual family income   <0.0001*  
$55000+ 10.89 (1.83) (7.29, 14.50)   
$25000 to <$55000 4.87 (1.70) (1.52, 8.22)   
<$25000 - -   
Smoking Status (self-reported)   0.03  
Non-Smoker 3.05 (1.43) (0.23, 5.86)   
Smoker - -   
Alcohol consumption Self-
reported) 
  <0.0003*  
Drinker 5.44 (1.49) (2.51, 8.38)   
Non-Drinker - -   
Diabetes (Self-reported)   <0.0018*  
No 5.64 (1.63) (2.44, 8.84)   
Yes - -   
Kidneys Problems   0.01  
No 5.57 (2.16) (1.32, 9.82)   
Yes - -   
Physical function limitations 
(Self-reported) 
    
Limitations that keeps individual 
from working 
  <0.0001*  
No 7.03 (1.79) (3.51, 10.55)   
Yes - -   
Experience confusion/memory 
problems 
  <0.0001*  
No 10.02 (2.09) (5.92, 14.12)   
Yes - -   
1 Log transformed 




Table 12 Multivariate model showing association between delay word recall test scores, total PAH in urine, 
and other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_Total1 (ng/L) -0.12 (0.06) (-0.25, -0.004) 0.04 0.13 
     
Age   <.0001*  
60-69 2.23 (0.26) (1.71, 2.76)   
70-79 1.53 (0.27) (0.98, 2.08)   
80+ - -   
Medical Conditions Self-
reported 
    
Coronary heart disease   <0.0008*  
No 1.18 (0.35) (0.49, 1.87)   
Yes - -   
1 Log transformed 
* p value was significant at 0.05 level 
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Table 13 Multivariate model showing association between delay word recall test scores, PAH (NFP) in urine, 
and other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_NFP1 (ng/L) -0.12 (0.06) (-0.25, -0.004) 0.04 0.13 
     
Age   <.0001*  
60-69 2.23 (0.26) (1.71, 2.76)   
70-79 1.53 (0.27) (0.98, 2.08)   
80+ - -   
Medical Conditions Self-
reported 
    
Coronary heart disease   <0.0008*  
No 1.18 (0.35) (0.49, 1.87)   
Yes - -   
1 Log transformed 




Table 14 Multivariate model showing association between delay word recall test scores, 1-Hydroxypyrene in 
urine, and other covariates, 2011-2014 NHANES participants 
Variable Estimate (SE)  95% CI P-value R2 
ln_1-OHPyr 1 (ng/L) 0.23 (0.09) (0.06, 0.42) <0.0091* 0.31 
     
Age   <0.0001*  
60-69 1.84 (0.24) (1.36, 2.32)   
70-79 1.30 (0.24) (0.81, 1.79)   
80+ - -   
Gender   <0.0001*  
Female 0.84 (0.18) (0.47, 1.21)   
Male -    
Race    <0.0006*  
Hispanic -0.71 (0.24) (-1.20, -0.23)   
Asians 0.10 (0.25) (-0.38, 0.60)   
Blacks  -0.64 (0.19) (-1.03, -0.26)   
Whites   - -   
Education Level   <0.0005*  
Less than high school -0.81 (0.25) -1.31, -0.31)   
High school graduate or GED -0.40 (0.24) (-0.88, 0.07)   
College graduate or higher 0.24 (0.25) (-0.25, 0.74)   
Some college - -   
Smoking Status (self-reported)   <0.0046*  
Non-Smoker 0.51 (0.18) (0.15, 0.86)   
Smoker - -   
Medical Conditions Self-
reported 
    
Memory and thinking problems   <0.0001*  
No 0.92 (0.26) (0.40, 1.43)   
Yes - -   
Physical function limitations 
(Self-reported) 
    
Experience confusion/memory 
problems 
  <0.0001*  
No 1.73 (0.32) (1.09, 2.38)   
Yes - -   
1 Log transformed 





Table 15 Multivariate model showing association between world list learning test scores, total PAH in urine, 
and other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_Total1 (ng/L) -0.27 (0.13) (-0.53, -0.02) 0.03 0.13 
     
Age   <.0001*  
60-69 4.18 (0.51) (3.16, 5.20)   
70-79 2.24 (0.57) (1.11, 3.38)   
80+ - -   
Diabetes (Self-reported)   <0.0081*  
No 1.30 (0.42) (0.46, 2.14)   
Yes - -   
Medical Conditions Self-
reported 
    
Coronary heart disease   <0.0063*  
No 1.78 (0.65) (0.50, 3.05)   
Yes - -   
1 Log transformed 




Table 16 Multivariate model showing association between world list learning test scores, PAH (NFP) in urine, 
and other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_NFP1 (ng/L) -0.27 (0.12) (-0.53, -0.02) 0.03 0.13 
     
Age   <.0001*  
60-69 4.18 (0.51) (3.16, 5.20)   
70-79 2.24 (0.57) (1.11, 3.38)   
80+ - -   
Diabetes (Self-reported)   <0.0081*  
No 1.30 (0.42) (0.46, 2.14)   
Yes - -   
Medical Conditions Self-
reported 
    
Coronary heart disease   <0.0063*  
No 1.78 (0.65) (0.50, 3.05)   
Yes - -   
1 Log transformed 





Table 17 Multivariate model showing association between animal fluency test scores, total PAH in urine, and 
other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_Total1 (ng/L) -0.39 (0.20) (-0.79, -0.0006) 0.04 0.21 
     
Age   <0.0001  
60-69 4.91 (0.55) (3.82, 6.01)   
70-79 2.69 (0.60) (1.51, 3.88)   
80+ - -   
Annual family income   <0.0017  
$55000+ 2.11 (0.59) (0.95, 3.27)   
$25000 to <$55000 0.62 (0.58) (-0.52, 1.77)   
<$25000 - -   
Alcohol consumption Self-
reported) 
  <0.0023  
Drinker 1.53 (0.50) (0.54, 2.52)   
Non-Drinker - -   
Kidneys Problems   0.02  
No 1.77 (0.79) (0.20, 3.34)   
Yes - -   
Physical Activity (Self-
reported) 
    
Vigorous recreational 
activities 
  <0.0026*  
No -3.55 (1.17) (-5.87, -1.24)   
Yes - -   
1 Log transformed 




Table 18 Multivariate model showing association between animal fluency test scores, PAH (NFP) in urine, and 
other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
ln_PAH_NFP1 (ng/L) -0.39 (0.20) (-0.78, -0.002) 0.051 0.21 
     
Age   <0.0001*  
60-69 4.91 (0.55) (3.82, 6.01)   
70-79 2.69 (0.60) (1.51, 3.88)   
80+ - -   
Annual family income   <0.0017*  
$55000+ 2.11 (0.59) (0.95, 3.27)   
$25000 to <$55000 0.62 (0.58) (-0.52, 1.77)   
<$25000 - -   
Alcohol consumption Self-
reported) 
  <0.0024*  
Drinker 1.53 (0.50) (0.54, 2.52)   
Non-Drinker - -   
Kidneys Problems   0.02  
No 1.77 (0.79) (0.20, 3.34)   
Yes - -   
Physical Activity (Self-
reported) 
    
Vigorous recreational 
activities 
  <0.0026*  
No -3.55 (1.17) (-5.87, -1.24)   
Yes - -   
1 Log transformed 














Table 19 Characteristics of NHANES participants for 2011-2014 
Characteristic N Percent (weighted) SE 
Age     
60-69 1671 54.67 1.19 
70-79 950 29.53 1.04 
80+ 560 15.79 0.73 
Gender    
Male 1547 45.32 1.23 
Female 1634 54.67 1.23 
Race     
Hispanic 615 7.50 0.34 
Asians 317 5.27 0.42 
Blacks 779 8.98 0.38 
Whites 1470 78.23 0.71 
Smoking Status     
Smoker 1601 50.26 1.23 
Non-Smoker 1577 49.73 1.23 
Alcohol consumption     
Yes 171 5.81 0.57 
No 2997 94.18 0.57 
Physical Activity     
Walk or bicycle     
Yes 666 18.98 0.98 
No 2515 81.01 0.98 
Body Mass Index (BMI)    
<25 844 26.17 1.08 
25-29.9 1091 36.03 1.19 
=>30 1184 37.78 1.20 
Hypertension    
HTN 3059 96.54 0.42 












Table 20 Univariate model showing the association between race and total PAH biomarkers in urine, and 
other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
Race    <0.0001* 0.01 
Hispanic 0.18 (0.10) (-0.02, 0.39)   
Asians 0.21 (0.25) (-0.29, 0.72)   
Blacks  0.58 (0.10) (0.38, 0.78)   
Whites   - -   
Smoking Status (Self-reported)   0.01 0.009 
Non-Smoker -0.24 (0.10) (-0.44, -0.04)   
Smoker - -   
* p value was significant at 0.05 level 
 
 
Table 21 Multivariate model showing the association between race and total PAH biomarkers in urine 
adjusted with other covariates, 2011-2014 NHANES participants 
Variable Estimate 
(SE)  
95% CI P-value R2 
Race    <0.0001* 0.03 
Hispanic 0.18 (0.10) (-0.02, 0.39)   
Asian 0.22 (0.25) (-0.28, 0.71)   
Blacks   0.61 (0.10) (-0.41, 0,81)   
Whites   - -   
Smoking Status (Self-reported)   <0.03  
Non-Smoker 0.59 (0.19) (0.20, 0.98)   
Smoker - -   
* p value was significant at 0.05 level 
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Table 22 Characteristics of 2011-2014 NHANES for hypertensive participants with urinary PAH metabolites 



































































































GM- geometric mean 
GSE- geometric standard error 
ng/L—nanograms per liter 
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Table 23 The probability of developing HTN with 2.5 ng/L of urinary 1-hydroxynaphthalene biomarker by 
































































































ng/L—nanograms per liter 
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Table 24 The probability of developing HTN with 5 ng/L of urinary 1-hydroxynaphthalene biomarker 
increased by different racial groups 










































Whites 5.00 3.5295 .4994 87 .07 .0001 .05 .5495 .5095 .9715 .01382 .9275 .9891 
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Table 25 The probability of developing HTN with 7.5 ng/L of urinary 1-hydroxynaphthalene biomarker 




















































ng/L—nanograms per liter 
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Table 26 The Odds ratio of developing HTN with urinary 1-hydroxynaphthalene biomarker measured by 































































































Table 27 Standard limits and regulations for PAH exposure (ATSDR, 2009b) 




Air: workplace 0.2 (mg/m3) for 
benzene-soluble coal 
tar pitch fraction 
Advisory: TLV (8-
hour TWA) 





0.1 mg/m3 for coal 









0.2 mg/m3 for 
benzene-soluble coal 
tar pitch fraction 
Regulation: (benzene 
soluble fraction of 
coal tar volatiles) 
PEL (8-hour 
workday) 
TLV: threshold limit value 
TWA: (time-weighted average): defined as a concentration for a normal 8-hour workday and a 40-
hour workweek that nearly all workers may be repeatedly exposed. 
REL (recommended exposure limit): recommended airborne exposure limit for CTPVs averaged 
over a 10-hour work shift. 
PEL (permissible exposure limit): the legal airborne permissible exposure limit for CTPVs 
averaged over an 8-hour work shift. 
(mg/L): milligrams per liter  
(mg/m3): milligrams per cubic meter  
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Table 28 Medications for patients with dementia (University Health System, 2012) 
Eligible population Line Medication Initial dose Maximum dose 
Mild cognitive 
impairment 
   Medications are not recommended  
Early-to midstage 
dementia 
1st Donepezil 5 mg daily for 4 weeks, 
then increase to 10 mg 
daily if tolerated 
10 mg daily1 
 2nd Galantamine 
Immediate 
release (NF) 
4 mg twice daily for 4 
weeks, then 8 mg twice 
daily for 4 weeks, then 
increase to 12 mg twice 
daily if tolerated. 
12 mg twice 
daily 
  Galantamine 
extended 
release (NF) 
8 mg daily x 4 weeks, 
16 mg daily x 4 weeks, 
then increase to 24 mg 
daily if tolerated 
24 mg daily 




1.5 mg twice daily for 
2 weeks, 3 mg twice 
daily for 2 weeks, 4.5 
mg twice daily for 2 
weeks, then increase to 
6 mg twice daily if 
tolerated 
6 mg twice 
daily 
  Rivastigmine 
transdermal 
patch (NF) 
4.6 mg daily for 4 
weeks, then 
increase to 9.5 mg daily 
if tolerated 
9.5 mg daily 
Mid-stage dementia 
no longer or too 





5 mg daily for 1 week, 
then 5 mg twice daily 
for 1 week, then 5 mg 
in the morning and 10 
mg in the evening for 1 
week, then 10 mg twice 
daily if tolerated. 
10 mg twice 
daily 
Late-stage dementia For this level of dementia, medications may be more harmful 




Table 29 Studies of measured PAH exposure and cognitive disorders among older adults (Humphreys and 
Hernández, 2021) 
Citation Sample  
Size   
Sample 
Characteristics   
Male:  




Range   
Comorbidities   Air Pollution Data 
Acquisition 
Method   
Du et al. 2020  697  
  
Employed at a coking 
plant in Shanxi 
province, China for 












The sum of the 
concentrations 
of eleven 
urinary PAH  
metabolites Σ-OHPAH  
  
Cho et al. 2020  949  
  
≥50 year-old 
individuals, no known 
neurological diseases, 
resident in Seoul, 
Incheon, Wonju and 
Pyeongchang, 



















Ha et al. 2012  565  
  
Volunteers in the 
Hebei Spirit 
oil spill, 
2007, near the 
shore of 












metabolites in  
urine   
  


















23 years to 48 
years 
12 


















resident in 15 
randomly 
selected states 







≥ 60 years  
  
Hypertension  
Thyroid Disease   
Stroke  
Kidney Disease   
Liver Disease   
The sum of the 
concentrations 
of eight  
urinary PAH  
metabolites (ΣOHPAH)  
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Table 30 Studies of measured PAH exposure and neurobehavioral development among childhood 
(Humphreys and Hernández, 2021) 
Citation   Samp
le  
Size   
Sample 
Characteristics   
Male:  





Range   
Co-
morbi 




Method   




Children aged 5-12 
resident in Nairobi, 
Kenya, Infected 
with HIV and 
previously enrolled 
in the Optimizing 
HIV-1  






















Children 7- 10 
years, resident and 
enrolled in one of 
40 schools in 
Barcelona, Spain, 






7 years - 10 
years 12 





air sampling   
  





years of age, Part 
of a civilian 
population resident 






6 years - 15 
years 12 














11, attending 1 of 
38 schools in 
Barcelona, Spain, 
and 1 school in the 
adjacent 
municipality, Sant 
Cugat del Vallés  





7 years- 11 
years 12 
months   
  












Table 31 Studies of measured prenatal PAH exposure and neurobehavioral development (Humphreys and 
Hernández, 2021) 
Citation   Sample  
Size   
Sample 
Characteristics   
Male:  





Range   
Air Pollution Data  
Acquisition  
Method   
Perera et 
al. 2018  
351  
  
Children 9 years 









for a minimum of 
a year in 
Washington 
Heights, Harlem 
or the South 
Bronx in New 
York City.  



























for a minimum of 
a year in 
Washington 
Heights, Harlem 
or the South 
Bronx in New 






6 years - 7 
years 12 
months   
  
Environmental 
samples analyzed for 
8 PAH  
Perera et 
al. 2011  
215  
  
Children 3 years 9 
months- 5 years 
11 months of age, 
mothers 18-35 
years, non-







3 years 9 
months - 5 
years 11 
months   
  












for a minimum of 
a year in 
Washington 
Heights, Harlem 
or the South 
Bronx in New 
York City.  
Pagliacci 




Children 11 years 
old, mothers 18-
35 years, non-







for a minimum of 
a year in 
Washington 
Heights, Harlem 
or the South 
Bronx in New 
York City.   





11 years - 




samples analysed for 
8 PAH  
Nie et 
al. 2019  
247  
  
Infants 3 days of 
age, mothers ≥ 18 
years, non-
smoking, no 
chronic disease or 





delivered in the 
Sixth Hospital of 
Shanxi Medical 
University and the 
Eighth People's 
Hospital of 










hydroxyfluorene   
111 
Taiyua, resident 
in Taiyuan for at 
least a year  
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Appendix A.2 Models 
Model  1. Individual univariate models of the association between digit symbol substitution test (DSST), 
urinary PAH biomarkers, and other covariates among 2011-2014 NHANES participants 
 
 
Model  2. Individual univariate models of the association between delayed word recall test (DWR), urinary 






Model  3. Individual univariate models of the association between world list learning test (WL), urinary PAH 




Model  4. Individual univariate models of the association between animal fluency test (AF), urinary PAH 







Model  5. Multivariate model of the association between digit symbol substitution test (DSST), urinary PAH 
biomarkers, and other covariates among 2011-2014 NHANES participants 
 
 
Model  6. Multivariate model of the association between delayed word recall test (DWR), urinary PAH 




Model  7. Multivariate model of the association between world list learning test (WL), urinary PAH 
biomarker, and other covariates among 2011-2014 NHANES participants 
 
 
Model  8. Multivariate model of the association between animal fluency test (AF), urinary PAH biomarker, 




Appendix A.3 Figures 
Appendix A.3 includes Residual plots and normal distribution charts for the outcome and 
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